{"gene":"BAX","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":1997,"finding":"Bax resides as a soluble cytosolic protein in healthy cells and translocates to mitochondria early during apoptosis (before nuclear condensation). Removal of the C-terminal hydrophobic domain inhibits this redistribution and abolishes death-promoting activity, demonstrating the C-terminal domain is required for both mitochondrial targeting and pro-apoptotic function.","method":"GFP-fusion live-cell confocal microscopy, FRAP, domain deletion mutagenesis in Cos-7 and L929 cells","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct live-cell localization with functional consequence, replicated across multiple cell lines and multiple orthogonal methods (FRAP, deletion mutants, death assays)","pmids":["9382873"],"is_preprint":false},{"year":1998,"finding":"Regulated mitochondrial membrane insertion of BAX is governed by discrete domains: the N-terminal domain represses the transmembrane signal-anchor function of the C-terminal domain, and in unstimulated cells this prevents mitochondrial insertion. A death signal relieves this inhibition; caspase activity (blocked by zVAD-fmk) partially mediates stimulated mitochondrial membrane insertion in vivo and is required in cell-free apoptotic extracts.","method":"Deletion and chimeric domain mutagenesis of BAX, in vivo targeting assays, cell-free mitochondrial targeting reconstitution, zVAD-fmk inhibitor treatment","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro reconstitution combined with domain mutagenesis and in vivo pharmacological inhibition, single lab but multiple orthogonal approaches","pmids":["9763432"],"is_preprint":false},{"year":2011,"finding":"Bcl-xL inhibits BAX by constantly retrotranslocating membrane-associated BAX from mitochondria back into the cytoplasm. FLIP analysis shows WT Bax but not conformationally tethered Bax undergoes retrotranslocation; inhibition of retrotranslocation causes BAX accumulation on mitochondria. Pro-survival BCL-2 family proteins are required for this retrotranslocation.","method":"Intramolecular disulfide tethering, fluorescence loss in photobleaching (FLIP), cell-free MOMP assay, Co-IP in detergents","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (FLIP, disulfide tethering, biochemical MOMP assay), mechanistically rigorous, single lab with strong internal controls","pmids":["21458670"],"is_preprint":false},{"year":2009,"finding":"BAX activation proceeds via stepwise structural reorganization: the α1 helix of BAX keeps the α9 helix engaged in the dimerization pocket, maintaining BAX as a cytosolic monomer. Direct-activator BH3-only proteins (tBID, BIM, PUMA) engage and expose the α1 helix, causing disengagement of α9 and mitochondrial insertion; these activators remain associated with N-terminally exposed BAX through the BH1 domain to drive homo-oligomerization.","method":"Domain mutagenesis, structural analysis, cell-based BAX targeting and oligomerization assays, BH3-only protein interaction studies","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — mechanistic mutagenesis combined with biochemical and cellular assays, single lab with multiple orthogonal methods","pmids":["19917256"],"is_preprint":false},{"year":2014,"finding":"A structural model of active membrane-inserted BAX was determined by DEER spectroscopy in liposomes and isolated mitochondria. Active BAX is organized as assemblies of dimers; each monomer contains a stable dimerization domain and a flexible piercing domain. The primary structural change during activation is opening of the α5-α6 hairpin into a clamp-like conformation central to mitochondrial membrane permeabilization.","method":"Double electron-electron resonance (DEER) EPR spectroscopy in liposomes and isolated mitochondria","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in situ structural method (DEER) in physiologically relevant membranes, single lab with rigorous biophysical approach","pmids":["25458844"],"is_preprint":false},{"year":2006,"finding":"In healthy cells, Bax (and Bak) is required for normal mitochondrial fusion. Bax promotes mitochondrial fusion by activating assembly of the large GTPase Mfn2 and altering its submitochondrial distribution and membrane mobility, properties that correlate with different GTP-bound states of Mfn2.","method":"Bax/Bak knockout cell analysis, live-cell imaging of mitochondrial morphology, Mfn2 distribution and mobility studies","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function with defined morphological phenotype, mechanistic link to Mfn2 GTPase, published in Nature with multiple lines of evidence","pmids":["17035996"],"is_preprint":false},{"year":2018,"finding":"BAK/BAX form macropores in the mitochondrial outer membrane during apoptosis that are large enough to allow the inner mitochondrial membrane to herniate into the cytosol, carrying mitochondrial matrix components including mtDNA, thereby enabling cGAS/STING pathway activation.","method":"Live-cell lattice light-sheet microscopy of mouse embryonic fibroblasts, super-resolution imaging, BAK/BAX genetic knockout","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct live-cell imaging with genetic controls, published in Science, novel mechanistic finding with high-resolution microscopy","pmids":["29472455"],"is_preprint":false},{"year":2016,"finding":"Active BAX clusters into distinct ring, arc, and linear oligomeric assemblies at mitochondria during apoptosis. Both complete rings and arc-shaped assemblies perforate the membrane, supporting a mechanism where BAX fully or partially delineates pores of different sizes.","method":"Dual-color single-molecule super-resolution localization microscopy, atomic force microscopy on lipid bilayers","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal high-resolution methods (SMLM + AFM), single lab but rigorous structural and functional evidence","pmids":["26783362"],"is_preprint":false},{"year":2018,"finding":"VDAC2 is specifically required for BAX (but not BAK) apoptotic function. Genetic deletion of VDAC2 abrogates BAX association with mitochondrial VDAC complexes and inhibits BAX-mediated apoptosis, phenocopying BAX loss in tumor suppression assays.","method":"Genome-wide CRISPR/Cas9 screen, VDAC2 genetic deletion, co-immunoprecipitation, tumor formation assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — unbiased genome-wide screen validated by genetic deletion and multiple biochemical and cellular assays","pmids":["30478310"],"is_preprint":false},{"year":2016,"finding":"VDAC2 serves as the mitochondrial platform for Bax retrotranslocation, ensuring mitochondria-specific membrane association of Bax. In the absence of VDAC2, Bax localizes to other cell compartments. Bax retrotranslocation is also regulated by nucleotides and calcium ions.","method":"Mitochondrial isolation, Bax retrotranslocation assay, VDAC2 genetic deletion, localization analysis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and biochemical evidence in single lab, multiple assays for retrotranslocation","pmids":["27620692"],"is_preprint":false},{"year":2003,"finding":"Bax and Bak can localize to the endoplasmic reticulum as well as to mitochondria. At the ER, Bax/Bak undergo conformational changes and oligomerization upon ER stress, leading to caspase-12 cleavage, progressive ER Ca2+ depletion, and a parallel caspase activation pathway distinct from the mitochondrial pathway.","method":"Organelle-targeted Bak mutant expression in bax-/-bak-/- cells, caspase-12 cleavage assay, ER Ca2+ measurement, caspase-7/PARP cleavage","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — targeted mutants selectively to ER vs. mitochondria with distinct functional readouts, orthogonal methods in single lab","pmids":["12847083"],"is_preprint":false},{"year":2012,"finding":"A small molecule (BTSA1-related compound) directly activates BAX by engaging the BAX trigger site (a distinct BH3-binding groove on BAX) as confirmed by NMR. Binding at this site promotes BAX oligomerization and induces BAX-dependent cell death without interacting with antiapoptotic BCL-2 proteins or BAK.","method":"Computational screening, NMR interaction analysis, biochemical oligomerization assay, BAX-dependent cell death assay","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structural validation combined with biochemical and cellular assays, single lab with multiple orthogonal methods","pmids":["22634637"],"is_preprint":false},{"year":2015,"finding":"The BCL-2 BH4 domain binds to a groove on BAX formed by α1, α1-α2 loop, and α2-α3/α5-α6 hairpins with nanomolar affinity, independently inhibiting BAX conformational activation. Hydrogen-deuterium exchange MS showed BH4 suppresses BIM BH3-induced N-terminal conformational changes in BAX—a noncanonical inhibitory mechanism distinct from the canonical BH3-groove sequestration.","method":"Hydrogen-deuterium exchange mass spectrometry, fluorescence polarization binding assay, structural localization by HDX-MS, BAX activation assay","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — HDX-MS structural validation with binding affinity measurement and functional inhibition assay, single lab but multiple orthogonal methods","pmids":["25684204"],"is_preprint":false},{"year":2016,"finding":"Cytosolic BAX exists in an autoinhibited inactive dimer conformation in addition to the monomer. Crystal structure of the inactive BAX dimer reveals an asymmetric interaction that inhibits the N-terminal conformational change of one protomer and displaces the C-terminal α9 helix of the second. This dimer must dissociate to monomers before BAX can be activated.","method":"Full-length crystal structure determination, cellular BAX activity assays, biochemical dimerization analysis","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with functional validation, single lab with structural and cellular orthogonal methods","pmids":["27425408"],"is_preprint":false},{"year":2019,"finding":"Small-molecule BAX inhibitors (BAIs) bind directly to a previously unrecognized pocket around helix α5 on BAX and allosterically inhibit BAX activation by stabilizing the hydrophobic core, preventing conformational changes required for mitochondrial translocation and oligomerization.","method":"NMR binding assay, biochemical BAX activation assay, cellular translocation and oligomerization analysis","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — NMR-based binding site identification with biochemical and cellular functional validation, single lab multiple orthogonal methods","pmids":["30718816"],"is_preprint":false},{"year":2017,"finding":"An NMR fragment screen identified a compound that sensitizes BAX activation by binding to a pocket at the junction of α3-α4 and α5-α6 hairpins, allosterically mobilizing the α1-α2 loop and BAX BH3 helix—two motifs implicated in activation and oligomerization of BAX.","method":"NMR-based fragment screen, HDX-MS structural analysis, biochemical BAX activation assay","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structural identification plus HDX-MS and biochemical validation, single lab with multiple orthogonal methods","pmids":["28692068"],"is_preprint":false},{"year":2022,"finding":"BAX physically interacts with DRP1, and this interaction is enhanced during apoptosis. Complex formation occurs exclusively in the membrane environment and requires the BAX N-terminal region. Forced dimerization of BAX and DRP1 triggers their co-activation and translocation to mitochondria, inducing mitochondrial remodeling and permeabilization. DRP1 can act as a noncanonical direct activator of BAX.","method":"Co-immunoprecipitation, super-resolution microscopy, forced dimerization constructs, mitochondrial permeabilization assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP with functional forced dimerization experiment and multiple imaging approaches, single lab but orthogonal methods","pmids":["35023587"],"is_preprint":false},{"year":2004,"finding":"ASC (apoptosis-associated speck-like protein) functions as an adaptor for BAX, directly interacting with BAX and colocalizing it to mitochondria. ASC induces cytochrome c release, reduces mitochondrial membrane potential, and activates caspase-9, -2, and -3. siRNA knockdown of ASC impairs BAX mitochondrial translocation in response to p53 or genotoxic stress. ASC induction after genotoxic stress depends on p53.","method":"Co-immunoprecipitation, siRNA knockdown, colocalization microscopy, caspase activation assay, mitochondrial membrane potential assay","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct Co-IP, siRNA functional validation, and multiple cellular readouts in single lab with orthogonal methods","pmids":["14730312"],"is_preprint":false},{"year":2005,"finding":"RASSF1A activates BAX via the Bax-binding protein MOAP-1. RASSF1A directly interacts with MOAP-1, and this interaction is enhanced by activated K-Ras. RASSF1A, MOAP-1, and activated K-Ras synergize to induce BAX activation and cell death. A tumor-derived RASSF1A point mutant defective for MOAP-1 interaction fails to activate BAX.","method":"Co-immunoprecipitation, BAX activation assay, shRNA knockdown, point mutant analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus functional BAX activation assay and loss-of-function mutant, single lab","pmids":["16344548"],"is_preprint":false},{"year":2007,"finding":"PKCζ directly phosphorylates BAX at serine 184 in vitro and in vivo. This phosphorylation prevents BAX conformational change and mitochondrial translocation, sequesters BAX in the cytoplasm, and prolongs cell survival. Purified PKCζ can directly dissociate BAX from isolated mitochondria of ceramide-treated cells. PKCζ and BAX interact at the BH3 domain.","method":"In vitro kinase assay with purified PKCζ and BAX, phospho-site-specific mutagenesis, co-immunoprecipitation, BAX mitochondrial dissociation assay, siRNA knockdown","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro kinase assay with mutagenesis validation plus multiple cellular assays, single lab","pmids":["17525161"],"is_preprint":false},{"year":2018,"finding":"Akt phosphorylates BAX at serine S184, converting BAX from pro-apoptotic to anti-apoptotic. Mechanistically, S184 phosphorylation enables BAX to bind pro-apoptotic activator BH3 proteins in solution, and prevents BAX insertion into mitochondria. This promotes sequestration of activator BH3 proteins and resistance to apoptosis.","method":"Phospho-site mutagenesis, BH3 protein binding assay, mitochondrial insertion assay, cellular apoptosis resistance assay","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — mutagenesis combined with biochemical binding assay and functional insertion assay, single lab with multiple orthogonal methods","pmids":["29987135"],"is_preprint":false},{"year":2011,"finding":"HDAC6 binds both Ku70 and BAX in the cytoplasm of neuroblastoma cells and maintains Ku70 in a deacetylated state that keeps BAX complexed with Ku70. Knockdown of HDAC6 or use of an HDAC6-specific inhibitor triggers Ku70 acetylation, BAX release from Ku70, and BAX-dependent cell death.","method":"Co-immunoprecipitation, HDAC6-specific inhibitor treatment, siRNA knockdown, cell death assay","journal":"Neoplasia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with pharmacological and genetic loss-of-function, single lab","pmids":["21847364"],"is_preprint":false},{"year":2000,"finding":"tBID (caspase-8 cleavage product of BID) directly or indirectly relieves inhibition of the BAX transmembrane signal-anchor by the N-terminal domain, resulting in BAX integration into mitochondrial membrane. However, a BID-independent pathway for BAX mitochondrial insertion also exists (shown in Bid-null MEFs), and cytochrome c release can be uncoupled from BAX membrane insertion in the absence of BID.","method":"In vivo and in vitro mitochondrial targeting reconstitution, Bid-null MEF genetics, caspase-8 cleavage assay","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro reconstitution with genetic null cells identifying parallel pathway, multiple approaches in single lab","pmids":["11139284"],"is_preprint":false},{"year":2009,"finding":"Bid activates BAX independently of stoichiometric ratio, suggesting Bid has a catalytic (transient) function. The nucleation event for BAX homo-oligomerization is formation of a stable dimerization interface involving two BH3 domains. EPR-based intermolecular distance measurements yielded a model of six adjacent BAX molecules where hydrophobic hairpins (helices α5-α6) are equally spaced in the membrane.","method":"Electron paramagnetic resonance (EPR) with spin-labeled Bax, atomic force microscopy, cryo-electron microscopy, liposome reconstitution","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple biophysical structural methods (EPR, AFM, cryo-EM) in reconstituted systems, single lab","pmids":["20008353"],"is_preprint":false},{"year":2006,"finding":"BCL-2 undergoes a conformational change in the mitochondrial membrane in response to apoptotic agonists (tBid, Bax). This conformational change is required to sequester membrane-inserted BAX monomers and prevent productive BAX oligomerization. A disulfide-tethered BCL-2 mutant (S105C/E152C) that restricts α5-α6 helix mobility is only active in reducing conditions, confirming helix mobility is required.","method":"Disulfide-tethered BCL-2 mutant, transfected cell and isolated mitochondria assays, tBid-induced oligomerization assay","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — engineered disulfide mutant with functional validation, single lab","pmids":["16642033"],"is_preprint":false},{"year":2012,"finding":"Human cytomegalovirus vMIA inhibits BAX by binding to a previously unknown regulatory site on BAX (distinct from canonical interaction sites), as determined by NMR structure of the BAX-vMIA peptide complex. Binding stabilizes key elements required for BAX MOM insertion and oligomerization. Mutants disrupting key intermolecular interactions impair vMIA-mediated mitochondrial recruitment of BAX and increase cytochrome c release.","method":"NMR structure determination of BAX-vMIA peptide complex, cellular BAX localization assay, cytochrome c release assay, charge-reversal interface rescue mutagenesis","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure with mutagenesis validation and cellular functional confirmation, single lab but multiple orthogonal approaches","pmids":["23213219"],"is_preprint":false},{"year":2007,"finding":"Bnip3 mediates mitochondrial dysfunction and cell death through Bax and Bak as downstream effectors. BAX/BAK double-deficient MEFs are completely resistant to hypoxia-induced cell death and Bnip3 overexpression, and re-expression of either Bax or Bak restores susceptibility. Bnip3 triggers GFP-Bax translocation to mitochondria during simulated ischemia-reperfusion.","method":"Bax/Bak double-knockout MEFs, genetic rescue with Bax or Bak re-expression, GFP-Bax live-cell imaging, mitochondrial membrane potential and cytochrome c assays","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with rescue experiment and multiple functional assays, single lab","pmids":["17447897"],"is_preprint":false},{"year":2015,"finding":"Mitochondrial size controlled by Mfn1-mediated fusion is required for productive BAX-membrane interactions. Cells with hyperfragmented mitochondria fail to support BAX-dependent membrane association and permeabilization due to an inability to stabilize BAX α9·membrane interactions. This was demonstrated in biochemical, cellular, in vivo, and size-restricted OMM model systems.","method":"Mfn1 genetic manipulation, size-restricted OMM model systems, BAX binding assay, MOMP measurement, in vivo and ex vivo studies","journal":"Molecular cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple complementary systems (biochemical, cellular, in vivo) identifying mechanistic link between mitochondrial size and BAX α9-membrane interaction, single lab","pmids":["25482509"],"is_preprint":false},{"year":2021,"finding":"Eltrombopag (FDA-approved drug) directly inhibits BAX by binding the BAX trigger site, preventing BH3-only activators from triggering BAX conformational transformation and simultaneously stabilizing the inactive BAX structure, thereby inhibiting BAX-mediated apoptosis.","method":"NMR binding assay, BAX conformational activation assay, cellular apoptosis assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — NMR-confirmed direct binding with functional inhibition assay, single lab with multiple orthogonal methods","pmids":["33602934"],"is_preprint":false},{"year":2018,"finding":"Parkin suppresses BAX-mediated apoptosis through an indirect mechanism (not via direct BAX ubiquitination), in contrast to its direct ubiquitination of BAK. The indirect mechanism of BAX suppression by Parkin during mitophagy was established by the absence of BAX ubiquitination alongside functional suppression of BAX activity.","method":"Ubiquitination assay, BAX/BAK-deficient genetic analysis, mitophagy induction, apoptosis assay","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — negative finding (no BAX ubiquitination) combined with functional assay; indirect mechanism proposed but not fully defined, single lab","pmids":["30573668"],"is_preprint":false},{"year":2015,"finding":"PGAM5L (long isoform) is required for Bax activation and its translocation to mitochondria during intrinsic apoptosis. A Bax-PGAM5L-Drp1 ternary complex forms during apoptosis; Bax transfection rescues triplex formation in Bax-null cells. Knockdown of PGAM5L inhibits Bax translocation and reduces mitochondrial fission.","method":"Co-immunoprecipitation, siRNA knockdown, Bax-null cell rescue, GFP-Bax translocation assay, in vivo tumor models","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, genetic rescue, and translocation assays in multiple models, single lab","pmids":["26356820"],"is_preprint":false},{"year":2019,"finding":"Cyclin C, released from the nucleus to cytoplasm during oxidative stress, directly co-immunoprecipitates with active BAX and binds recombinant BAX in vitro. Cytoplasmic cyclin C is required for both normal BAX activation and efficient BAX mitochondrial localization. Stable cyclin C-BAX association requires the fission complex.","method":"Co-immunoprecipitation of endogenous proteins, in vitro binding with recombinant BAX, cyclin C nuclear release manipulation, BAX activation and localization assay","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in vitro binding plus Co-IP and functional localization data, single lab","pmids":["31385392"],"is_preprint":false},{"year":2009,"finding":"Bax activates endophilin B1 (Endo B1) oligomerization in a cell-free system: purified Bax induces Endo B1 to assemble into high-molecular-weight oligomers via the Endo B1 C-terminal SH3 domain, without Bax stably associating with the final complex. Together, Bax plus Endo B1 induces massive vesiculation of giant unilamellar vesicles, suggesting Bax regulates mitochondrial membrane remodeling via transient Endo B1 activation.","method":"Cell-free reconstitution with purified proteins, size-exclusion chromatography, giant unilamellar vesicle assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro reconstitution establishing transient Bax-Endo B1 interaction and functional membrane vesiculation, single lab","pmids":["19805544"],"is_preprint":false},{"year":2010,"finding":"Prostaglandin E2 (PGE2) directly binds BAX and induces a conformational change that triggers apoptosis. Cys126 in the loop between the two transmembrane α-helices is critical for PGE2-induced BAX activation. PGD2 antagonizes PGE2 binding to BAX and inhibits PGE2-induced apoptosis, establishing a PGE2/PGD2 balance as a regulatory mechanism for BAX activation.","method":"Direct binding assay (PGE2-BAX), cysteine mutagenesis, apoptosis assays with multiple stimuli","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding with mutagenesis and multiple functional apoptosis assays, single lab","pmids":["20966963"],"is_preprint":false},{"year":2014,"finding":"BAX directly permeabilizes lysosomal membranes (lysosomal membrane permeabilization, LMP) in Parkinson disease models. Recombinant BAX induces LMP in purified mouse brain lysosomes; pharmacological blockade of BAX channel activity prevents LMP. BAX translocates to lysosomal membranes early after MPTP treatment, preceding mitochondrial permeabilization.","method":"Recombinant BAX LMP assay in purified lysosomes, BAX channel inhibitor treatment, in vivo and in vitro BAX translocation assay","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro reconstitution with purified lysosomes plus pharmacological validation in vivo and in vitro, single lab","pmids":["24686337"],"is_preprint":false},{"year":2008,"finding":"Cholesterol in membrane bilayers inhibits BAX pore-forming activity by reducing the ability of BAX to transition from a membrane-associated to a membrane-integral state. Cholesterol increases BAX binding to membranes but markedly reduces integration into both liposomal and mitochondrial membranes.","method":"In vitro BAX membrane binding/integration assay with defined liposomes and isolated human mitochondria, cholesterol titration","journal":"Journal of molecular biology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified BAX and defined membranes, mechanistic dissection of binding vs. integration steps, single lab","pmids":["18590739"],"is_preprint":false},{"year":2024,"finding":"Unsaturated lipids are enriched in the proximal membrane environment of BAX and BAK during apoptosis. Unsaturated lipids promote BAX pore activity in model membranes, isolated mitochondria, and cellular systems. The fatty acid desaturase FADS2 enhances both apoptosis sensitivity and cGAS/STING pathway activation downstream of mtDNA release.","method":"Comparative lipidomics of BAK in lipid nanodiscs, BAX pore activity assay in model membranes and isolated mitochondria, FADS2 manipulation, molecular dynamics simulations","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — lipidomics identification with functional reconstitution in multiple systems and MD simulation support, single lab","pmids":["38830851"],"is_preprint":false},{"year":2008,"finding":"TCTP antagonizes apoptosis by inserting into the mitochondrial membrane and inhibiting BAX dimerization. Crystal structure of human TCTP at 2.0 Å revealed structural similarity between TCTP H2-H3 helices and BAX H5-H6 helices. Site-directed mutagenesis of H2-H3 abolished TCTP's anti-apoptotic function.","method":"Crystal structure determination (2.0 Å), site-directed mutagenesis of TCTP, mitochondrial insertion assay, BAX dimerization inhibition assay","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with mutagenesis and functional validation, single lab with multiple orthogonal methods","pmids":["18274553"],"is_preprint":false},{"year":2018,"finding":"Cytosolic BAX exists as an ensemble of conformers; distribution within this ensemble determines function. Crystal structure of BAX P168G mutant near the C-terminus and antibody 3C10 binding near the N-terminus both inhibit BAX by limiting exposure of membrane-associating helix α9, supporting an allosteric conformational ensemble model of BAX regulation.","method":"Crystal structure determination of BAX P168G and BAX-3C10 antibody complex, functional cytosolic BAX inhibition assays","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures with functional validation, single lab","pmids":["30122452"],"is_preprint":false},{"year":2015,"finding":"DRAM1 directly interacts with BAX, inhibits BAX autophagic degradation, recruits BAX to lysosomes, and thereby promotes BAX-mediated lysosomal cathepsin B release, tBID cleavage, and mitochondrial cytochrome c release. BAX at lysosomes thus initiates a lysosome-cathepsin B-tBID pathway leading to apoptosis.","method":"Co-immunoprecipitation, BAX protein stability assay, lysosomal fractionation, cathepsin B release assay, cytochrome c release assay","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with multiple functional assays identifying novel BAX localization-function link at lysosomes, single lab","pmids":["25633293"],"is_preprint":false}],"current_model":"BAX is a cytosolic, predominantly monomeric (also forming an autoinhibited inactive dimer) pro-apoptotic BCL-2 family protein that, upon apoptotic signaling, undergoes N-terminal conformational activation (triggered by direct-activator BH3-only proteins such as tBID, BIM, PUMA binding a distinct trigger site on BAX), exposes its C-terminal hydrophobic domain for mitochondrial targeting (facilitated by VDAC2 as a membrane platform), oligomerizes at the mitochondrial outer membrane (MOM) through symmetric BH3:groove dimers that further assemble via α6-helix interfaces into rings, arcs, and higher-order structures forming heterogeneous pores (lipidic and/or proteinaceous) that permeabilize the MOM to release cytochrome c and mtDNA; BAX activity is counteracted by pro-survival BCL-2 proteins (notably BCL-xL, which retrotranslocates BAX from mitochondria back to cytosol via VDAC2) and by phosphorylation (Akt at S184, PKCζ at S184) that sequesters BAX in the cytosol; additionally, BAX regulates mitochondrial fusion by activating Mfn2, can permeabilize ER and lysosomal membranes, and its macropores enable herniation of the inner mitochondrial membrane carrying mtDNA to activate innate immune cGAS/STING signaling."},"narrative":{"mechanistic_narrative":"BAX is a pro-apoptotic BCL-2 family protein that executes mitochondrial outer membrane permeabilization (MOMP), the committed step of intrinsic apoptosis [PMID:9382873, PMID:26783362]. In healthy cells BAX is held inactive in the cytosol as a conformational ensemble of monomers and an autoinhibited dimer in which the N-terminal α1 helix keeps the C-terminal α9 transmembrane signal-anchor sequestered in the dimerization pocket, preventing mitochondrial insertion [PMID:27425408, PMID:30122452, PMID:19917256, PMID:9763432]. A death signal relieves this autoinhibition: direct-activator BH3-only proteins (tBID, BIM, PUMA) engage a distinct trigger site, expose α1, disengage α9, and drive mitochondrial targeting and homo-oligomerization, with BID acting catalytically and through both BID-dependent and BID-independent routes [PMID:19917256, PMID:22634637, PMID:11139284, PMID:20008353]. Membrane-inserted BAX undergoes opening of the α5–α6 hairpin and assembles into symmetric dimers that further organize into rings, arcs, and linear oligomers forming pores of variable size [PMID:25458844, PMID:26783362, PMID:20008353]. These pores enlarge into macropores permitting inner-membrane herniation and release of cytochrome c and mtDNA, the latter activating cGAS/STING innate-immune signaling [PMID:29472455, PMID:38830851]. VDAC2 serves as the mitochondria-specific platform governing BAX association and is selectively required for BAX (not BAK) apoptotic function [PMID:30478310, PMID:27620692]. BAX activity is opposed by pro-survival proteins—BCL-xL drives retrotranslocation of membrane BAX back to the cytosol, BCL-2 sequesters inserted monomers, and the BCL-2 BH4 domain noncanonically suppresses BAX N-terminal activation [PMID:21458670, PMID:16642033, PMID:25684204]—and by inhibitory phosphorylation at Ser184 by Akt and PKCζ that retains BAX in the cytosol [PMID:17525161, PMID:29987135]. Beyond apoptosis, BAX promotes mitochondrial fusion by activating the GTPase Mfn2 in healthy cells and can also permeabilize endoplasmic reticulum and lysosomal membranes [PMID:17035996, PMID:12847083, PMID:24686337]. The membrane environment, including mitochondrial size, cholesterol, and unsaturated lipids, tunes BAX integration and pore activity [PMID:25482509, PMID:18590739, PMID:38830851].","teleology":[{"year":1997,"claim":"Established that BAX is a cytosolic protein that relocates to mitochondria at the onset of apoptosis and that its C-terminal hydrophobic domain is essential for both targeting and killing, defining the spatial logic of BAX activation.","evidence":"GFP-fusion live-cell confocal microscopy, FRAP, and domain-deletion death assays in Cos-7/L929 cells","pmids":["9382873"],"confidence":"High","gaps":["Did not define what represses targeting in healthy cells","Molecular trigger for translocation unresolved"]},{"year":1998,"claim":"Showed that the N-terminal domain represses the C-terminal signal-anchor and that a death signal (partly caspase-dependent) relieves this, explaining how membrane insertion is held in check until apoptosis.","evidence":"Domain/chimeric mutagenesis, in vivo and cell-free targeting reconstitution, zVAD-fmk inhibition","pmids":["9763432"],"confidence":"High","gaps":["Identity of the relieving factor not pinned down","Caspase role only partial"]},{"year":2000,"claim":"Identified tBID as a trigger that relieves N-terminal repression of insertion, while revealing a parallel BID-independent route and uncoupling cytochrome c release from BAX insertion under some conditions.","evidence":"In vivo/in vitro mitochondrial targeting reconstitution and Bid-null MEF genetics","pmids":["11139284"],"confidence":"High","gaps":["Nature of the BID-independent pathway unresolved","Stoichiometry of activation not defined"]},{"year":2003,"claim":"Demonstrated BAX/BAK act at the ER as well as mitochondria, defining a parallel ER-stress caspase-12 pathway and broadening BAX's organellar reach.","evidence":"Organelle-targeted Bak mutants in bax-/-bak-/- cells, caspase-12 cleavage and ER Ca2+ assays","pmids":["12847083"],"confidence":"High","gaps":["How BAX selects ER vs mitochondria unclear","Relevance of caspase-12 pathway across species"]},{"year":2004,"claim":"Identified ASC as a p53-dependent adaptor coupling genotoxic stress to BAX mitochondrial translocation, linking upstream stress signaling to BAX activation.","evidence":"Co-IP, siRNA knockdown, colocalization, caspase activation assays","pmids":["14730312"],"confidence":"High","gaps":["Direct binding interface not mapped","Whether ASC activates or merely chaperones BAX unclear"]},{"year":2006,"claim":"Revealed a non-death role: BAX promotes mitochondrial fusion in healthy cells by activating Mfn2, showing BAX function is not restricted to apoptosis.","evidence":"Bax/Bak knockout cells, live-cell morphology imaging, Mfn2 distribution/mobility studies","pmids":["17035996"],"confidence":"High","gaps":["Direct biochemical mechanism of Mfn2 activation undefined","How this role is partitioned from apoptotic function unclear"]},{"year":2006,"claim":"Showed BCL-2 sequesters membrane-inserted BAX monomers via a tBid/Bax-induced conformational change requiring α5–α6 helix mobility, defining a post-insertion inhibitory checkpoint.","evidence":"Disulfide-tethered BCL-2 mutant in cells and isolated mitochondria","pmids":["16642033"],"confidence":"Medium","gaps":["Engineered mutant; physiological conformer not directly observed","Single lab"]},{"year":2007,"claim":"Established direct phosphorylation of BAX at Ser184 by PKCζ as a survival switch that prevents conformational change and dissociates BAX from mitochondria, defining post-translational suppression.","evidence":"In vitro kinase assay with purified proteins, phospho-site mutagenesis, Co-IP, mitochondrial dissociation assay","pmids":["17525161"],"confidence":"High","gaps":["Physiological contexts of PKCζ regulation of BAX limited","Structural basis of S184 effect not resolved"]},{"year":2009,"claim":"Defined the stepwise activation mechanism whereby α1 keeps α9 in the dimerization pocket and direct activators expose α1 to release α9, with activators remaining engaged to drive oligomerization.","evidence":"Domain mutagenesis, structural analysis, cellular targeting/oligomerization and BH3 interaction assays","pmids":["19917256"],"confidence":"High","gaps":["Transient nature of activator engagement not quantified","Membrane requirement not addressed structurally"]},{"year":2009,"claim":"Provided a biophysical oligomer model showing BH3:groove dimers nucleate assembly and that BID acts catalytically, establishing the structural unit of the BAX pore.","evidence":"EPR with spin-labeled Bax, AFM, cryo-EM, liposome reconstitution","pmids":["20008353"],"confidence":"High","gaps":["Higher-order assembly geometry incompletely resolved","Pore lipidic vs proteinaceous nature unsettled"]},{"year":2009,"claim":"Showed BAX transiently activates endophilin B1 oligomerization to vesiculate membranes, implicating BAX in mitochondrial membrane remodeling beyond pore formation.","evidence":"Cell-free reconstitution with purified proteins, SEC, GUV vesiculation assay","pmids":["19805544"],"confidence":"Medium","gaps":["In vitro only; cellular relevance not established","BAX does not stably associate, so mechanism transient and hard to validate"]},{"year":2011,"claim":"Defined BCL-xL inhibition as continuous retrotranslocation of membrane BAX back to the cytosol, reframing pro-survival control as a dynamic spatial mechanism rather than static sequestration.","evidence":"Disulfide tethering, FLIP, cell-free MOMP assay, Co-IP","pmids":["21458670"],"confidence":"High","gaps":["Molecular machinery of transport step not fully defined","How activation overrides retrotranslocation unclear"]},{"year":2011,"claim":"Identified HDAC6/Ku70 as a cytosolic restraint that holds BAX inactive in a deacetylated-Ku70 complex, linking acetylation status to BAX availability.","evidence":"Co-IP, HDAC6 inhibitor, siRNA knockdown, cell death assay in neuroblastoma","pmids":["21847364"],"confidence":"Medium","gaps":["Direct vs indirect binding not separated","Generality beyond neuroblastoma untested"]},{"year":2012,"claim":"Identified a distinct BAX trigger site by NMR using a direct small-molecule activator, establishing that BAX can be activated independently of antiapoptotic proteins or BAK.","evidence":"Computational screen, NMR interaction analysis, oligomerization and death assays","pmids":["22634637"],"confidence":"High","gaps":["In-cell occupancy of the trigger site not measured","Endogenous ligand of trigger site unknown at this stage"]},{"year":2012,"claim":"Solved the BAX-vMIA complex by NMR, revealing a viral inhibitory site distinct from canonical surfaces, illustrating an additional regulatable surface on BAX.","evidence":"NMR structure of BAX-vMIA peptide, cellular localization and cytochrome c assays, interface rescue mutagenesis","pmids":["23213219"],"confidence":"High","gaps":["Physiological host counterpart of this site unknown","Mechanism limited to viral context"]},{"year":2014,"claim":"Determined an in-membrane structural model showing active BAX as dimer assemblies with a flexible piercing domain and α5–α6 clamp opening as the central permeabilizing change.","evidence":"DEER EPR spectroscopy in liposomes and isolated mitochondria","pmids":["25458844"],"confidence":"High","gaps":["Atomic-resolution pore structure still lacking","Higher-order ring/arc connectivity not resolved here"]},{"year":2014,"claim":"Showed BAX can directly permeabilize lysosomal membranes early in Parkinson disease models, extending pore activity to a non-mitochondrial organelle.","evidence":"Recombinant BAX LMP assay in purified lysosomes, channel inhibitor, in vivo/in vitro translocation","pmids":["24686337"],"confidence":"Medium","gaps":["Targeting determinants for lysosomes vs mitochondria unknown","Single disease model"]},{"year":2015,"claim":"Defined a noncanonical inhibitory mechanism in which the BCL-2 BH4 domain binds a defined groove on BAX to suppress N-terminal activation, distinct from BH3-groove sequestration.","evidence":"HDX-MS, fluorescence polarization binding, BAX activation assay","pmids":["25684204"],"confidence":"High","gaps":["Cellular contribution relative to canonical sequestration unquantified","Structural complex not crystallized"]},{"year":2015,"claim":"Showed mitochondrial size controlled by Mfn1-mediated fusion is required for productive BAX α9·membrane interactions, linking organelle morphology to permeabilization competence.","evidence":"Mfn1 manipulation, size-restricted OMM models, BAX binding and MOMP assays in vitro/in vivo","pmids":["25482509"],"confidence":"Medium","gaps":["Biophysical basis of size dependence incomplete","Single lab"]},{"year":2015,"claim":"Identified PGAM5L as required for BAX activation/translocation via a Bax-PGAM5L-Drp1 ternary complex, connecting BAX to the fission machinery.","evidence":"Co-IP, siRNA, Bax-null rescue, GFP-Bax translocation, tumor models","pmids":["26356820"],"confidence":"Medium","gaps":["Direct vs scaffold role of PGAM5L unclear","Interaction interfaces unmapped"]},{"year":2015,"claim":"Showed DRAM1 binds BAX, blocks its autophagic degradation, and recruits it to lysosomes to initiate a cathepsin B–tBID amplification loop, defining a lysosome-initiated apoptotic route for BAX.","evidence":"Co-IP, stability assay, lysosomal fractionation, cathepsin B and cytochrome c release assays","pmids":["25633293"],"confidence":"Medium","gaps":["Direct binding interface unmapped","Generality of lysosomal BAX route uncertain"]},{"year":2016,"claim":"Visualized BAX organizing into rings, arcs, and linear assemblies that perforate membranes, establishing that pores can be fully or partially delineated and vary in size.","evidence":"Dual-color SMLM super-resolution and AFM on lipid bilayers","pmids":["26783362"],"confidence":"High","gaps":["Lipidic vs proteinaceous pore character unresolved","Determinants of arc vs ring choice unknown"]},{"year":2016,"claim":"Solved the autoinhibited inactive BAX dimer crystal structure, showing an asymmetric interaction that must dissociate to monomers before activation, defining a cytosolic restraint state.","evidence":"Full-length crystal structure, cellular activity and dimerization assays","pmids":["27425408"],"confidence":"High","gaps":["Fraction of BAX in dimer vs monomer in cells unclear","Trigger for dissociation undefined"]},{"year":2016,"claim":"Established VDAC2 as the mitochondrial platform ensuring mitochondria-specific BAX retrotranslocation, also tuned by nucleotides and calcium.","evidence":"Mitochondrial isolation, retrotranslocation assay, VDAC2 deletion, localization analysis","pmids":["27620692"],"confidence":"Medium","gaps":["Mechanism of VDAC2-BAX coupling not structurally defined","Where BAX goes without VDAC2 only partly characterized"]},{"year":2017,"claim":"Identified an allosteric sensitizer pocket at the α3–α4/α5–α6 junction that mobilizes the α1–α2 loop and BAX BH3 helix, mapping a druggable activation-promoting surface.","evidence":"NMR fragment screen, HDX-MS, biochemical activation assay","pmids":["28692068"],"confidence":"High","gaps":["In-cell efficacy of sensitizers limited","Endogenous ligand of pocket unknown"]},{"year":2018,"claim":"Showed BAK/BAX macropores allow inner-membrane herniation and mtDNA release that activates cGAS/STING, connecting MOMP to innate immune signaling.","evidence":"Lattice light-sheet and super-resolution imaging of MEFs with BAK/BAX knockout","pmids":["29472455"],"confidence":"High","gaps":["Molecular control of macropore enlargement unclear","Timing relative to caspase activation not fully mapped"]},{"year":2018,"claim":"Established Akt phosphorylation at Ser184 as an apoptosis-to-survival switch that lets BAX bind and sequester activator BH3 proteins while blocking insertion, defining a converging Ser184 regulatory node.","evidence":"Phospho-mutagenesis, BH3 binding assay, insertion and apoptosis-resistance assays","pmids":["29987135"],"confidence":"High","gaps":["Structural basis of converted BH3-binding behavior unresolved","Interplay with PKCζ at the same site untested"]},{"year":2018,"claim":"Demonstrated cytosolic BAX is a conformational ensemble whose distribution sets function, with structures showing α9 exposure as the key tunable element.","evidence":"Crystal structures of BAX P168G and BAX-3C10 antibody complex, inhibition assays","pmids":["30122452"],"confidence":"High","gaps":["How upstream signals bias the ensemble undefined","Quantitative populations in cells unknown"]},{"year":2018,"claim":"Established VDAC2 as selectively required for BAX (not BAK) apoptotic function via an unbiased screen, defining a BAX-specific dependency.","evidence":"Genome-wide CRISPR screen, VDAC2 deletion, Co-IP, tumor formation assays","pmids":["30478310"],"confidence":"High","gaps":["Whether VDAC2 directly forms the pore platform vs acts as receptor unclear","Structural BAX-VDAC2 interface unresolved"]},{"year":2018,"claim":"Showed Parkin suppresses BAX indirectly (no BAX ubiquitination), contrasting with direct BAK ubiquitination and revealing mechanistic divergence between the two effectors during mitophagy.","evidence":"Ubiquitination assay, BAX/BAK-deficient analysis, mitophagy and apoptosis assays","pmids":["30573668"],"confidence":"Medium","gaps":["Indirect mechanism not defined","Negative finding; intermediary unknown"]},{"year":2019,"claim":"Defined an allosteric inhibitory pocket near α5 targeted by small-molecule BAIs that stabilize the hydrophobic core and block translocation/oligomerization, providing a pharmacological off-switch.","evidence":"NMR binding, biochemical activation, cellular translocation/oligomerization assays","pmids":["30718816"],"confidence":"High","gaps":["In-cell selectivity and potency limited","No endogenous regulator of this pocket identified"]},{"year":2019,"claim":"Identified cytoplasmic cyclin C, released during oxidative stress, as a direct BAX-binding factor required for efficient activation and mitochondrial localization, linking stress-driven nuclear release to BAX.","evidence":"Co-IP of endogenous proteins, in vitro binding with recombinant BAX, localization assays","pmids":["31385392"],"confidence":"Medium","gaps":["Binding interface unmapped","Requirement for fission complex mechanistically unexplained"]},{"year":2022,"claim":"Showed BAX physically interacts with DRP1 in membranes via its N-terminus and that DRP1 can act as a noncanonical direct activator, integrating the fission GTPase into BAX activation.","evidence":"Reciprocal Co-IP, super-resolution imaging, forced dimerization, permeabilization assay","pmids":["35023587"],"confidence":"High","gaps":["How DRP1 activation compares to BH3-only activators unclear","In vivo contribution to apoptosis not quantified"]},{"year":2024,"claim":"Demonstrated that unsaturated lipids enrich around BAX/BAK and promote pore activity, and that FADS2 enhances apoptosis and cGAS/STING activation, defining lipid composition as a determinant of permeabilization.","evidence":"Comparative lipidomics in nanodiscs, pore assays in model membranes/mitochondria/cells, FADS2 manipulation, MD simulations","pmids":["38830851"],"confidence":"High","gaps":["Mechanism by which unsaturation favors integration not atomically defined","Physiological regulation of local lipid pool unclear"]},{"year":null,"claim":"It remains unresolved whether the BAX pore is fundamentally lipidic, proteinaceous, or hybrid, and what unifies the diverse activating inputs (BH3-only proteins, DRP1, cyclin C, PGAM5L, ASC, prostaglandins) into a single quantitative model of pore formation.","evidence":"","pmids":[],"confidence":"Low","gaps":["No atomic-resolution structure of the assembled BAX pore","No integrated kinetic model reconciling the many activators and inhibitors","Determinants of organelle selectivity (mitochondria vs ER vs lysosome) undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[35,36,33]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[4,7,23]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,16,32]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,6,7,8]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,2,13,38]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[10]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[34,39]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,3,22,6]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[5,27]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,36]}],"complexes":[],"partners":["BCL2L1","VDAC2","BID","DNM1L","MFN2","BCL2","PYCARD","PGAM5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q07812","full_name":"Apoptosis regulator BAX","aliases":["Bcl-2-like protein 4","Bcl2-L-4"],"length_aa":192,"mass_kda":21.2,"function":"Plays a role in the mitochondrial apoptotic process (PubMed:10772918, PubMed:11060313, PubMed:16113678, PubMed:16199525, PubMed:18948948, PubMed:21199865, PubMed:21458670, PubMed:25609812, PubMed:36361894, PubMed:8358790, PubMed:8521816). Under normal conditions, BAX is largely cytosolic via constant retrotranslocation from mitochondria to the cytosol mediated by BCL2L1/Bcl-xL, which avoids accumulation of toxic BAX levels at the mitochondrial outer membrane (MOM) (PubMed:21458670). Under stress conditions, undergoes a conformation change that causes translocation to the mitochondrion membrane, leading to the release of cytochrome c that then triggers apoptosis (PubMed:10772918, PubMed:11060313, PubMed:16113678, PubMed:16199525, PubMed:18948948, PubMed:21199865, PubMed:21458670, PubMed:25609812, PubMed:8358790, PubMed:8521816). Promotes activation of CASP3, and thereby apoptosis (PubMed:10772918, PubMed:11060313, PubMed:16113678, PubMed:16199525, PubMed:18948948, PubMed:21199865, PubMed:21458670, PubMed:25609812, PubMed:8358790, PubMed:8521816)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q07812/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BAX","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BAX","total_profiled":1310},"omim":[{"mim_id":"621072","title":"BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 8; BIRC8","url":"https://www.omim.org/entry/621072"},{"mim_id":"621003","title":"TRANSCRIPTION FACTOR Sp9; SP9","url":"https://www.omim.org/entry/621003"},{"mim_id":"620751","title":"RETROTRANSPOSON GAG-LIKE 10; RTL10","url":"https://www.omim.org/entry/620751"},{"mim_id":"620701","title":"TETRATRICOPEPTIDE REPEAT DOMAIN 36; TTC36","url":"https://www.omim.org/entry/620701"},{"mim_id":"620311","title":"PREMATURE OVARIAN FAILURE 21; POF21","url":"https://www.omim.org/entry/620311"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BAX"},"hgnc":{"alias_symbol":["BCL2L4"],"prev_symbol":[]},"alphafold":{"accession":"Q07812","domains":[{"cath_id":"1.10.437.10","chopping":"17-36_54-190","consensus_level":"high","plddt":92.2875,"start":17,"end":190}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07812","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q07812-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q07812-F1-predicted_aligned_error_v6.png","plddt_mean":85.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BAX","jax_strain_url":"https://www.jax.org/strain/search?query=BAX"},"sequence":{"accession":"Q07812","fasta_url":"https://rest.uniprot.org/uniprotkb/Q07812.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q07812/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07812"}},"corpus_meta":[{"pmid":"9382873","id":"PMC_9382873","title":"Movement of Bax from the cytosol to mitochondria during apoptosis.","date":"1997","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9382873","citation_count":1532,"is_preprint":false},{"pmid":"29472455","id":"PMC_29472455","title":"BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis.","date":"2018","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/29472455","citation_count":854,"is_preprint":false},{"pmid":"28755482","id":"PMC_28755482","title":"Bax, Bak and beyond - mitochondrial performance in apoptosis.","date":"2017","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/28755482","citation_count":732,"is_preprint":false},{"pmid":"9024662","id":"PMC_9024662","title":"Bax suppresses tumorigenesis and stimulates apoptosis in vivo.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9024662","citation_count":578,"is_preprint":false},{"pmid":"9763432","id":"PMC_9763432","title":"Regulated targeting of BAX to mitochondria.","date":"1998","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9763432","citation_count":535,"is_preprint":false},{"pmid":"17035996","id":"PMC_17035996","title":"Role of Bax and Bak in mitochondrial morphogenesis.","date":"2006","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/17035996","citation_count":520,"is_preprint":false},{"pmid":"21458670","id":"PMC_21458670","title":"Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol.","date":"2011","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21458670","citation_count":506,"is_preprint":false},{"pmid":"19917256","id":"PMC_19917256","title":"Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis.","date":"2009","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/19917256","citation_count":501,"is_preprint":false},{"pmid":"12847083","id":"PMC_12847083","title":"Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis.","date":"2003","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12847083","citation_count":496,"is_preprint":false},{"pmid":"12818176","id":"PMC_12818176","title":"JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis.","date":"2003","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/12818176","citation_count":434,"is_preprint":false},{"pmid":"21195116","id":"PMC_21195116","title":"Molecular biology of Bax and Bak activation and action.","date":"2010","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21195116","citation_count":413,"is_preprint":false},{"pmid":"14634023","id":"PMC_14634023","title":"p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14634023","citation_count":308,"is_preprint":false},{"pmid":"11522774","id":"PMC_11522774","title":"Prion protein protects human neurons against Bax-mediated apoptosis.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11522774","citation_count":289,"is_preprint":false},{"pmid":"9454845","id":"PMC_9454845","title":"Bax involvement in p53-mediated neuronal cell death.","date":"1998","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/9454845","citation_count":281,"is_preprint":false},{"pmid":"17453158","id":"PMC_17453158","title":"Bax activation and mitochondrial insertion during apoptosis.","date":"2007","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/17453158","citation_count":276,"is_preprint":false},{"pmid":"12244308","id":"PMC_12244308","title":"Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis.","date":"2002","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12244308","citation_count":247,"is_preprint":false},{"pmid":"26783362","id":"PMC_26783362","title":"Bax assembly into rings and arcs in apoptotic mitochondria is linked to membrane pores.","date":"2016","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/26783362","citation_count":242,"is_preprint":false},{"pmid":"34848097","id":"PMC_34848097","title":"Physiological and pharmacological modulation of BAX.","date":"2021","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34848097","citation_count":237,"is_preprint":false},{"pmid":"17046225","id":"PMC_17046225","title":"How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane?","date":"2006","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/17046225","citation_count":235,"is_preprint":false},{"pmid":"19641510","id":"PMC_19641510","title":"Bid: a Bax-like BH3 protein.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/19641510","citation_count":234,"is_preprint":false},{"pmid":"16642033","id":"PMC_16642033","title":"Bcl-2 changes conformation to inhibit Bax oligomerization.","date":"2006","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/16642033","citation_count":220,"is_preprint":false},{"pmid":"14730312","id":"PMC_14730312","title":"ASC is a Bax adaptor and regulates the p53-Bax mitochondrial apoptosis pathway.","date":"2004","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/14730312","citation_count":204,"is_preprint":false},{"pmid":"17410096","id":"PMC_17410096","title":"The pathological role of Bax in cisplatin nephrotoxicity.","date":"2007","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/17410096","citation_count":196,"is_preprint":false},{"pmid":"26395559","id":"PMC_26395559","title":"Direct Activation of Bax Protein for Cancer Therapy.","date":"2015","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/26395559","citation_count":187,"is_preprint":false},{"pmid":"25458844","id":"PMC_25458844","title":"Structural model of active Bax at the membrane.","date":"2014","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/25458844","citation_count":187,"is_preprint":false},{"pmid":"17447897","id":"PMC_17447897","title":"Bnip3 mediates mitochondrial dysfunction and cell death through Bax and Bak.","date":"2007","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/17447897","citation_count":181,"is_preprint":false},{"pmid":"25482509","id":"PMC_25482509","title":"Mitochondrial shape governs BAX-induced membrane permeabilization and apoptosis.","date":"2014","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/25482509","citation_count":173,"is_preprint":false},{"pmid":"11836241","id":"PMC_11836241","title":"Bax and Bak independently promote cytochrome C release from mitochondria.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11836241","citation_count":170,"is_preprint":false},{"pmid":"18274553","id":"PMC_18274553","title":"TCTP protects from apoptotic cell death by antagonizing bax function.","date":"2008","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/18274553","citation_count":167,"is_preprint":false},{"pmid":"9695020","id":"PMC_9695020","title":"Bax. The pro-apoptotic Bcl-2 family member, Bax.","date":"1998","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9695020","citation_count":159,"is_preprint":false},{"pmid":"20008353","id":"PMC_20008353","title":"Molecular details of Bax activation, oligomerization, and membrane insertion.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20008353","citation_count":153,"is_preprint":false},{"pmid":"27932064","id":"PMC_27932064","title":"Bax and Bak Pores: Are We Closing the Circle?","date":"2016","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27932064","citation_count":152,"is_preprint":false},{"pmid":"30478310","id":"PMC_30478310","title":"VDAC2 enables BAX to mediate apoptosis and limit tumor development.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30478310","citation_count":152,"is_preprint":false},{"pmid":"12729579","id":"PMC_12729579","title":"Mitochondrial membrane permeabilisation by Bax/Bak.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12729579","citation_count":146,"is_preprint":false},{"pmid":"15784164","id":"PMC_15784164","title":"HSP60, Bax, apoptosis and the heart.","date":"2005","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15784164","citation_count":145,"is_preprint":false},{"pmid":"22634637","id":"PMC_22634637","title":"Direct and selective small-molecule activation of proapoptotic BAX.","date":"2012","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/22634637","citation_count":138,"is_preprint":false},{"pmid":"9190211","id":"PMC_9190211","title":"Bax- and Bak-induced cell death in the fission yeast Schizosaccharomyces pombe.","date":"1997","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/9190211","citation_count":137,"is_preprint":false},{"pmid":"35023587","id":"PMC_35023587","title":"DRP1 interacts directly with BAX to induce its activation and apoptosis.","date":"2022","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/35023587","citation_count":122,"is_preprint":false},{"pmid":"16344548","id":"PMC_16344548","title":"The RASSF1A tumor suppressor activates Bax via MOAP-1.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16344548","citation_count":120,"is_preprint":false},{"pmid":"25684204","id":"PMC_25684204","title":"Inhibition of Pro-apoptotic BAX by a noncanonical interaction mechanism.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/25684204","citation_count":117,"is_preprint":false},{"pmid":"27498846","id":"PMC_27498846","title":"Physiological and Pharmacological Control of BAK, BAX, and Beyond.","date":"2016","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27498846","citation_count":114,"is_preprint":false},{"pmid":"12242152","id":"PMC_12242152","title":"BAX and BAK mediate p53-independent suppression of tumorigenesis.","date":"2002","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/12242152","citation_count":109,"is_preprint":false},{"pmid":"21641962","id":"PMC_21641962","title":"Bax: Addressed to kill.","date":"2011","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/21641962","citation_count":108,"is_preprint":false},{"pmid":"11139284","id":"PMC_11139284","title":"BID-dependent and BID-independent pathways for BAX insertion into mitochondria.","date":"2000","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/11139284","citation_count":102,"is_preprint":false},{"pmid":"30573668","id":"PMC_30573668","title":"Parkin inhibits BAK and BAX apoptotic function by distinct mechanisms during mitophagy.","date":"2018","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/30573668","citation_count":94,"is_preprint":false},{"pmid":"26356820","id":"PMC_26356820","title":"Bax-PGAM5L-Drp1 complex is required for intrinsic apoptosis execution.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26356820","citation_count":91,"is_preprint":false},{"pmid":"21847364","id":"PMC_21847364","title":"HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma.","date":"2011","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/21847364","citation_count":90,"is_preprint":false},{"pmid":"20926580","id":"PMC_20926580","title":"BAX-dependent and BAX-independent regulation of Kiss1 neuron development in mice.","date":"2010","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20926580","citation_count":88,"is_preprint":false},{"pmid":"30718816","id":"PMC_30718816","title":"Small-molecule allosteric inhibitors of BAX.","date":"2019","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/30718816","citation_count":84,"is_preprint":false},{"pmid":"25633293","id":"PMC_25633293","title":"DRAM1 regulates apoptosis through increasing protein levels and lysosomal localization of BAX.","date":"2015","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/25633293","citation_count":83,"is_preprint":false},{"pmid":"29987135","id":"PMC_29987135","title":"Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance.","date":"2018","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/29987135","citation_count":83,"is_preprint":false},{"pmid":"17635151","id":"PMC_17635151","title":"Bax-inhibiting peptides derived from Ku70 and cell-penetrating pentapeptides.","date":"2007","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/17635151","citation_count":81,"is_preprint":false},{"pmid":"19745831","id":"PMC_19745831","title":"Single-cell quantification of Bax activation and mathematical modelling suggest pore formation on minimal mitochondrial Bax accumulation.","date":"2009","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/19745831","citation_count":80,"is_preprint":false},{"pmid":"31209350","id":"PMC_31209350","title":"Targeting BAX to drug death directly.","date":"2019","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/31209350","citation_count":79,"is_preprint":false},{"pmid":"19557009","id":"PMC_19557009","title":"Bax activation by Bim?","date":"2009","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/19557009","citation_count":79,"is_preprint":false},{"pmid":"15358121","id":"PMC_15358121","title":"Bax-inhibiting peptide derived from mouse and rat Ku70.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15358121","citation_count":76,"is_preprint":false},{"pmid":"17395004","id":"PMC_17395004","title":"Cathepsin D-Bax death pathway in oxidative stressed neuroblastoma cells.","date":"2007","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17395004","citation_count":76,"is_preprint":false},{"pmid":"11932420","id":"PMC_11932420","title":"Bak and Bax function to limit adenovirus replication through apoptosis induction.","date":"2002","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/11932420","citation_count":73,"is_preprint":false},{"pmid":"17616717","id":"PMC_17616717","title":"BAX regulates follicular endowment in mice.","date":"2007","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/17616717","citation_count":72,"is_preprint":false},{"pmid":"27425408","id":"PMC_27425408","title":"An Autoinhibited Dimeric Form of BAX Regulates the BAX Activation Pathway.","date":"2016","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/27425408","citation_count":71,"is_preprint":false},{"pmid":"27620692","id":"PMC_27620692","title":"The porin VDAC2 is the mitochondrial platform for Bax retrotranslocation.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27620692","citation_count":71,"is_preprint":false},{"pmid":"24686337","id":"PMC_24686337","title":"BAX channel activity mediates lysosomal disruption linked to Parkinson disease.","date":"2014","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/24686337","citation_count":71,"is_preprint":false},{"pmid":"20709625","id":"PMC_20709625","title":"Multistep and multitask Bax activation.","date":"2010","source":"Mitochondrion","url":"https://pubmed.ncbi.nlm.nih.gov/20709625","citation_count":68,"is_preprint":false},{"pmid":"16479009","id":"PMC_16479009","title":"Androgen and its receptor promote Bax-mediated apoptosis.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16479009","citation_count":68,"is_preprint":false},{"pmid":"19278624","id":"PMC_19278624","title":"Hydrogen peroxide-induced Akt phosphorylation regulates Bax activation.","date":"2009","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/19278624","citation_count":67,"is_preprint":false},{"pmid":"21297665","id":"PMC_21297665","title":"Bax inhibitor 1 in apoptosis and disease.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21297665","citation_count":65,"is_preprint":false},{"pmid":"24991825","id":"PMC_24991825","title":"BCL2 and related prosurvival proteins require BAK1 and BAX to affect autophagy.","date":"2014","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/24991825","citation_count":64,"is_preprint":false},{"pmid":"12217750","id":"PMC_12217750","title":"Bax, Bcl-2, and p53 expression in endometrial cancer.","date":"2002","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12217750","citation_count":63,"is_preprint":false},{"pmid":"28630157","id":"PMC_28630157","title":"Pore formation by dimeric Bak and Bax: an unusual pore?","date":"2017","source":"Philosophical transactions of the Royal Society of London. Series B, Biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28630157","citation_count":60,"is_preprint":false},{"pmid":"17525161","id":"PMC_17525161","title":"Protein kinase Czeta abrogates the proapoptotic function of Bax through phosphorylation.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17525161","citation_count":60,"is_preprint":false},{"pmid":"23744350","id":"PMC_23744350","title":"Consequences of the combined loss of BOK and BAK or BOK and BAX.","date":"2013","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/23744350","citation_count":59,"is_preprint":false},{"pmid":"38830851","id":"PMC_38830851","title":"Lipid unsaturation promotes BAX and BAK pore activity during apoptosis.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38830851","citation_count":56,"is_preprint":false},{"pmid":"23213219","id":"PMC_23213219","title":"Structural mechanism of Bax inhibition by cytomegalovirus protein vMIA.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23213219","citation_count":56,"is_preprint":false},{"pmid":"24825107","id":"PMC_24825107","title":"Activation of Bax in three models of retinitis pigmentosa.","date":"2014","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/24825107","citation_count":54,"is_preprint":false},{"pmid":"16916719","id":"PMC_16916719","title":"Decreased expression of tumour suppressor Bax-interacting factor-1 (Bif-1), a Bax activator, in gastric carcinomas.","date":"2006","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16916719","citation_count":54,"is_preprint":false},{"pmid":"33602934","id":"PMC_33602934","title":"Eltrombopag directly inhibits BAX and prevents cell death.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33602934","citation_count":50,"is_preprint":false},{"pmid":"35347233","id":"PMC_35347233","title":"BAX and BAK dynamics control mitochondrial DNA release during apoptosis.","date":"2022","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/35347233","citation_count":49,"is_preprint":false},{"pmid":"18948940","id":"PMC_18948940","title":"Apoptosis: Stabbed in the BAX.","date":"2008","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/18948940","citation_count":49,"is_preprint":false},{"pmid":"28630156","id":"PMC_28630156","title":"Apoptotic foci at mitochondria: in and around Bax pores.","date":"2017","source":"Philosophical transactions of the Royal Society of London. Series B, Biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28630156","citation_count":48,"is_preprint":false},{"pmid":"15138206","id":"PMC_15138206","title":"Bax translocation and mitochondrial fragmentation induced by Helicobacter pylori.","date":"2004","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/15138206","citation_count":47,"is_preprint":false},{"pmid":"31719602","id":"PMC_31719602","title":"Completion of BAX recruitment correlates with mitochondrial fission during apoptosis.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31719602","citation_count":46,"is_preprint":false},{"pmid":"26763134","id":"PMC_26763134","title":"Regulation of Bax/mitochondria interaction by AKT.","date":"2015","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/26763134","citation_count":45,"is_preprint":false},{"pmid":"25632145","id":"PMC_25632145","title":"Bax regulates neuronal Ca2+ homeostasis.","date":"2015","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25632145","citation_count":44,"is_preprint":false},{"pmid":"12879966","id":"PMC_12879966","title":"Cell death, Bcl-2, Bax, and the cerebellum.","date":"2002","source":"Cerebellum (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12879966","citation_count":43,"is_preprint":false},{"pmid":"20966963","id":"PMC_20966963","title":"Prostaglandins antagonistically control Bax activation during apoptosis.","date":"2010","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/20966963","citation_count":43,"is_preprint":false},{"pmid":"18508723","id":"PMC_18508723","title":"Higher expression of Bax in regulatory T cells increases vascular inflammation.","date":"2008","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/18508723","citation_count":43,"is_preprint":false},{"pmid":"37224250","id":"PMC_37224250","title":"Mitophagy restricts BAX/BAK-independent, Parkin-mediated apoptosis.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/37224250","citation_count":41,"is_preprint":false},{"pmid":"30122452","id":"PMC_30122452","title":"Ensemble Properties of Bax Determine Its Function.","date":"2018","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/30122452","citation_count":41,"is_preprint":false},{"pmid":"19805544","id":"PMC_19805544","title":"Bax activates endophilin B1 oligomerization and lipid membrane vesiculation.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19805544","citation_count":41,"is_preprint":false},{"pmid":"10772918","id":"PMC_10772918","title":"Characterization of Bax-sigma, a cell death-inducing isoform of Bax.","date":"2000","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10772918","citation_count":40,"is_preprint":false},{"pmid":"31841271","id":"PMC_31841271","title":"BAX inhibitor-1: between stress and survival.","date":"2020","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/31841271","citation_count":39,"is_preprint":false},{"pmid":"28692068","id":"PMC_28692068","title":"Allosteric sensitization of proapoptotic BAX.","date":"2017","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/28692068","citation_count":39,"is_preprint":false},{"pmid":"30836793","id":"PMC_30836793","title":"Pharmacological inhibition of Bax-induced cell death: Bax-inhibiting peptides and small compounds inhibiting Bax.","date":"2019","source":"Experimental biology and medicine (Maywood, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/30836793","citation_count":38,"is_preprint":false},{"pmid":"21441714","id":"PMC_21441714","title":"Bid and Bax are involved in granulosa cell apoptosis during follicular atresia in porcine ovaries.","date":"2011","source":"The Journal of reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/21441714","citation_count":38,"is_preprint":false},{"pmid":"18590739","id":"PMC_18590739","title":"Cholesterol effects on BAX pore activation.","date":"2008","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18590739","citation_count":38,"is_preprint":false},{"pmid":"18175815","id":"PMC_18175815","title":"Mitochondria potential, bax \"activation,\" and programmed cell death.","date":"2008","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/18175815","citation_count":37,"is_preprint":false},{"pmid":"22719850","id":"PMC_22719850","title":"A BAX/BAK and cyclophilin D-independent intrinsic apoptosis pathway.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22719850","citation_count":35,"is_preprint":false},{"pmid":"16353209","id":"PMC_16353209","title":"Expression of the Bax inhibitor-1 gene in pulmonary adenocarcinoma.","date":"2006","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16353209","citation_count":34,"is_preprint":false},{"pmid":"18655197","id":"PMC_18655197","title":"Bax shuttling after neonatal hypoxia-ischemia: hyperoxia effects.","date":"2008","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/18655197","citation_count":32,"is_preprint":false},{"pmid":"31385392","id":"PMC_31385392","title":"Mitochondrial translocation of cyclin C stimulates intrinsic apoptosis through Bax recruitment.","date":"2019","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/31385392","citation_count":32,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":42586,"output_tokens":9799,"usd":0.137372,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20431,"output_tokens":8593,"usd":0.15849,"stage2_stop_reason":"end_turn"},"total_usd":0.295862,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"Bax resides as a soluble cytosolic protein in healthy cells and translocates to mitochondria early during apoptosis (before nuclear condensation). Removal of the C-terminal hydrophobic domain inhibits this redistribution and abolishes death-promoting activity, demonstrating the C-terminal domain is required for both mitochondrial targeting and pro-apoptotic function.\",\n      \"method\": \"GFP-fusion live-cell confocal microscopy, FRAP, domain deletion mutagenesis in Cos-7 and L929 cells\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct live-cell localization with functional consequence, replicated across multiple cell lines and multiple orthogonal methods (FRAP, deletion mutants, death assays)\",\n      \"pmids\": [\"9382873\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Regulated mitochondrial membrane insertion of BAX is governed by discrete domains: the N-terminal domain represses the transmembrane signal-anchor function of the C-terminal domain, and in unstimulated cells this prevents mitochondrial insertion. A death signal relieves this inhibition; caspase activity (blocked by zVAD-fmk) partially mediates stimulated mitochondrial membrane insertion in vivo and is required in cell-free apoptotic extracts.\",\n      \"method\": \"Deletion and chimeric domain mutagenesis of BAX, in vivo targeting assays, cell-free mitochondrial targeting reconstitution, zVAD-fmk inhibitor treatment\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro reconstitution combined with domain mutagenesis and in vivo pharmacological inhibition, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"9763432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Bcl-xL inhibits BAX by constantly retrotranslocating membrane-associated BAX from mitochondria back into the cytoplasm. FLIP analysis shows WT Bax but not conformationally tethered Bax undergoes retrotranslocation; inhibition of retrotranslocation causes BAX accumulation on mitochondria. Pro-survival BCL-2 family proteins are required for this retrotranslocation.\",\n      \"method\": \"Intramolecular disulfide tethering, fluorescence loss in photobleaching (FLIP), cell-free MOMP assay, Co-IP in detergents\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (FLIP, disulfide tethering, biochemical MOMP assay), mechanistically rigorous, single lab with strong internal controls\",\n      \"pmids\": [\"21458670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BAX activation proceeds via stepwise structural reorganization: the α1 helix of BAX keeps the α9 helix engaged in the dimerization pocket, maintaining BAX as a cytosolic monomer. Direct-activator BH3-only proteins (tBID, BIM, PUMA) engage and expose the α1 helix, causing disengagement of α9 and mitochondrial insertion; these activators remain associated with N-terminally exposed BAX through the BH1 domain to drive homo-oligomerization.\",\n      \"method\": \"Domain mutagenesis, structural analysis, cell-based BAX targeting and oligomerization assays, BH3-only protein interaction studies\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mechanistic mutagenesis combined with biochemical and cellular assays, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"19917256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A structural model of active membrane-inserted BAX was determined by DEER spectroscopy in liposomes and isolated mitochondria. Active BAX is organized as assemblies of dimers; each monomer contains a stable dimerization domain and a flexible piercing domain. The primary structural change during activation is opening of the α5-α6 hairpin into a clamp-like conformation central to mitochondrial membrane permeabilization.\",\n      \"method\": \"Double electron-electron resonance (DEER) EPR spectroscopy in liposomes and isolated mitochondria\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in situ structural method (DEER) in physiologically relevant membranes, single lab with rigorous biophysical approach\",\n      \"pmids\": [\"25458844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In healthy cells, Bax (and Bak) is required for normal mitochondrial fusion. Bax promotes mitochondrial fusion by activating assembly of the large GTPase Mfn2 and altering its submitochondrial distribution and membrane mobility, properties that correlate with different GTP-bound states of Mfn2.\",\n      \"method\": \"Bax/Bak knockout cell analysis, live-cell imaging of mitochondrial morphology, Mfn2 distribution and mobility studies\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function with defined morphological phenotype, mechanistic link to Mfn2 GTPase, published in Nature with multiple lines of evidence\",\n      \"pmids\": [\"17035996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BAK/BAX form macropores in the mitochondrial outer membrane during apoptosis that are large enough to allow the inner mitochondrial membrane to herniate into the cytosol, carrying mitochondrial matrix components including mtDNA, thereby enabling cGAS/STING pathway activation.\",\n      \"method\": \"Live-cell lattice light-sheet microscopy of mouse embryonic fibroblasts, super-resolution imaging, BAK/BAX genetic knockout\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct live-cell imaging with genetic controls, published in Science, novel mechanistic finding with high-resolution microscopy\",\n      \"pmids\": [\"29472455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Active BAX clusters into distinct ring, arc, and linear oligomeric assemblies at mitochondria during apoptosis. Both complete rings and arc-shaped assemblies perforate the membrane, supporting a mechanism where BAX fully or partially delineates pores of different sizes.\",\n      \"method\": \"Dual-color single-molecule super-resolution localization microscopy, atomic force microscopy on lipid bilayers\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal high-resolution methods (SMLM + AFM), single lab but rigorous structural and functional evidence\",\n      \"pmids\": [\"26783362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"VDAC2 is specifically required for BAX (but not BAK) apoptotic function. Genetic deletion of VDAC2 abrogates BAX association with mitochondrial VDAC complexes and inhibits BAX-mediated apoptosis, phenocopying BAX loss in tumor suppression assays.\",\n      \"method\": \"Genome-wide CRISPR/Cas9 screen, VDAC2 genetic deletion, co-immunoprecipitation, tumor formation assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — unbiased genome-wide screen validated by genetic deletion and multiple biochemical and cellular assays\",\n      \"pmids\": [\"30478310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"VDAC2 serves as the mitochondrial platform for Bax retrotranslocation, ensuring mitochondria-specific membrane association of Bax. In the absence of VDAC2, Bax localizes to other cell compartments. Bax retrotranslocation is also regulated by nucleotides and calcium ions.\",\n      \"method\": \"Mitochondrial isolation, Bax retrotranslocation assay, VDAC2 genetic deletion, localization analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and biochemical evidence in single lab, multiple assays for retrotranslocation\",\n      \"pmids\": [\"27620692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Bax and Bak can localize to the endoplasmic reticulum as well as to mitochondria. At the ER, Bax/Bak undergo conformational changes and oligomerization upon ER stress, leading to caspase-12 cleavage, progressive ER Ca2+ depletion, and a parallel caspase activation pathway distinct from the mitochondrial pathway.\",\n      \"method\": \"Organelle-targeted Bak mutant expression in bax-/-bak-/- cells, caspase-12 cleavage assay, ER Ca2+ measurement, caspase-7/PARP cleavage\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — targeted mutants selectively to ER vs. mitochondria with distinct functional readouts, orthogonal methods in single lab\",\n      \"pmids\": [\"12847083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A small molecule (BTSA1-related compound) directly activates BAX by engaging the BAX trigger site (a distinct BH3-binding groove on BAX) as confirmed by NMR. Binding at this site promotes BAX oligomerization and induces BAX-dependent cell death without interacting with antiapoptotic BCL-2 proteins or BAK.\",\n      \"method\": \"Computational screening, NMR interaction analysis, biochemical oligomerization assay, BAX-dependent cell death assay\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structural validation combined with biochemical and cellular assays, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"22634637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The BCL-2 BH4 domain binds to a groove on BAX formed by α1, α1-α2 loop, and α2-α3/α5-α6 hairpins with nanomolar affinity, independently inhibiting BAX conformational activation. Hydrogen-deuterium exchange MS showed BH4 suppresses BIM BH3-induced N-terminal conformational changes in BAX—a noncanonical inhibitory mechanism distinct from the canonical BH3-groove sequestration.\",\n      \"method\": \"Hydrogen-deuterium exchange mass spectrometry, fluorescence polarization binding assay, structural localization by HDX-MS, BAX activation assay\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — HDX-MS structural validation with binding affinity measurement and functional inhibition assay, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"25684204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Cytosolic BAX exists in an autoinhibited inactive dimer conformation in addition to the monomer. Crystal structure of the inactive BAX dimer reveals an asymmetric interaction that inhibits the N-terminal conformational change of one protomer and displaces the C-terminal α9 helix of the second. This dimer must dissociate to monomers before BAX can be activated.\",\n      \"method\": \"Full-length crystal structure determination, cellular BAX activity assays, biochemical dimerization analysis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with functional validation, single lab with structural and cellular orthogonal methods\",\n      \"pmids\": [\"27425408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Small-molecule BAX inhibitors (BAIs) bind directly to a previously unrecognized pocket around helix α5 on BAX and allosterically inhibit BAX activation by stabilizing the hydrophobic core, preventing conformational changes required for mitochondrial translocation and oligomerization.\",\n      \"method\": \"NMR binding assay, biochemical BAX activation assay, cellular translocation and oligomerization analysis\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — NMR-based binding site identification with biochemical and cellular functional validation, single lab multiple orthogonal methods\",\n      \"pmids\": [\"30718816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"An NMR fragment screen identified a compound that sensitizes BAX activation by binding to a pocket at the junction of α3-α4 and α5-α6 hairpins, allosterically mobilizing the α1-α2 loop and BAX BH3 helix—two motifs implicated in activation and oligomerization of BAX.\",\n      \"method\": \"NMR-based fragment screen, HDX-MS structural analysis, biochemical BAX activation assay\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structural identification plus HDX-MS and biochemical validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"28692068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BAX physically interacts with DRP1, and this interaction is enhanced during apoptosis. Complex formation occurs exclusively in the membrane environment and requires the BAX N-terminal region. Forced dimerization of BAX and DRP1 triggers their co-activation and translocation to mitochondria, inducing mitochondrial remodeling and permeabilization. DRP1 can act as a noncanonical direct activator of BAX.\",\n      \"method\": \"Co-immunoprecipitation, super-resolution microscopy, forced dimerization constructs, mitochondrial permeabilization assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP with functional forced dimerization experiment and multiple imaging approaches, single lab but orthogonal methods\",\n      \"pmids\": [\"35023587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ASC (apoptosis-associated speck-like protein) functions as an adaptor for BAX, directly interacting with BAX and colocalizing it to mitochondria. ASC induces cytochrome c release, reduces mitochondrial membrane potential, and activates caspase-9, -2, and -3. siRNA knockdown of ASC impairs BAX mitochondrial translocation in response to p53 or genotoxic stress. ASC induction after genotoxic stress depends on p53.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, colocalization microscopy, caspase activation assay, mitochondrial membrane potential assay\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct Co-IP, siRNA functional validation, and multiple cellular readouts in single lab with orthogonal methods\",\n      \"pmids\": [\"14730312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"RASSF1A activates BAX via the Bax-binding protein MOAP-1. RASSF1A directly interacts with MOAP-1, and this interaction is enhanced by activated K-Ras. RASSF1A, MOAP-1, and activated K-Ras synergize to induce BAX activation and cell death. A tumor-derived RASSF1A point mutant defective for MOAP-1 interaction fails to activate BAX.\",\n      \"method\": \"Co-immunoprecipitation, BAX activation assay, shRNA knockdown, point mutant analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus functional BAX activation assay and loss-of-function mutant, single lab\",\n      \"pmids\": [\"16344548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PKCζ directly phosphorylates BAX at serine 184 in vitro and in vivo. This phosphorylation prevents BAX conformational change and mitochondrial translocation, sequesters BAX in the cytoplasm, and prolongs cell survival. Purified PKCζ can directly dissociate BAX from isolated mitochondria of ceramide-treated cells. PKCζ and BAX interact at the BH3 domain.\",\n      \"method\": \"In vitro kinase assay with purified PKCζ and BAX, phospho-site-specific mutagenesis, co-immunoprecipitation, BAX mitochondrial dissociation assay, siRNA knockdown\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro kinase assay with mutagenesis validation plus multiple cellular assays, single lab\",\n      \"pmids\": [\"17525161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Akt phosphorylates BAX at serine S184, converting BAX from pro-apoptotic to anti-apoptotic. Mechanistically, S184 phosphorylation enables BAX to bind pro-apoptotic activator BH3 proteins in solution, and prevents BAX insertion into mitochondria. This promotes sequestration of activator BH3 proteins and resistance to apoptosis.\",\n      \"method\": \"Phospho-site mutagenesis, BH3 protein binding assay, mitochondrial insertion assay, cellular apoptosis resistance assay\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutagenesis combined with biochemical binding assay and functional insertion assay, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"29987135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HDAC6 binds both Ku70 and BAX in the cytoplasm of neuroblastoma cells and maintains Ku70 in a deacetylated state that keeps BAX complexed with Ku70. Knockdown of HDAC6 or use of an HDAC6-specific inhibitor triggers Ku70 acetylation, BAX release from Ku70, and BAX-dependent cell death.\",\n      \"method\": \"Co-immunoprecipitation, HDAC6-specific inhibitor treatment, siRNA knockdown, cell death assay\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with pharmacological and genetic loss-of-function, single lab\",\n      \"pmids\": [\"21847364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"tBID (caspase-8 cleavage product of BID) directly or indirectly relieves inhibition of the BAX transmembrane signal-anchor by the N-terminal domain, resulting in BAX integration into mitochondrial membrane. However, a BID-independent pathway for BAX mitochondrial insertion also exists (shown in Bid-null MEFs), and cytochrome c release can be uncoupled from BAX membrane insertion in the absence of BID.\",\n      \"method\": \"In vivo and in vitro mitochondrial targeting reconstitution, Bid-null MEF genetics, caspase-8 cleavage assay\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro reconstitution with genetic null cells identifying parallel pathway, multiple approaches in single lab\",\n      \"pmids\": [\"11139284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Bid activates BAX independently of stoichiometric ratio, suggesting Bid has a catalytic (transient) function. The nucleation event for BAX homo-oligomerization is formation of a stable dimerization interface involving two BH3 domains. EPR-based intermolecular distance measurements yielded a model of six adjacent BAX molecules where hydrophobic hairpins (helices α5-α6) are equally spaced in the membrane.\",\n      \"method\": \"Electron paramagnetic resonance (EPR) with spin-labeled Bax, atomic force microscopy, cryo-electron microscopy, liposome reconstitution\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple biophysical structural methods (EPR, AFM, cryo-EM) in reconstituted systems, single lab\",\n      \"pmids\": [\"20008353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"BCL-2 undergoes a conformational change in the mitochondrial membrane in response to apoptotic agonists (tBid, Bax). This conformational change is required to sequester membrane-inserted BAX monomers and prevent productive BAX oligomerization. A disulfide-tethered BCL-2 mutant (S105C/E152C) that restricts α5-α6 helix mobility is only active in reducing conditions, confirming helix mobility is required.\",\n      \"method\": \"Disulfide-tethered BCL-2 mutant, transfected cell and isolated mitochondria assays, tBid-induced oligomerization assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — engineered disulfide mutant with functional validation, single lab\",\n      \"pmids\": [\"16642033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Human cytomegalovirus vMIA inhibits BAX by binding to a previously unknown regulatory site on BAX (distinct from canonical interaction sites), as determined by NMR structure of the BAX-vMIA peptide complex. Binding stabilizes key elements required for BAX MOM insertion and oligomerization. Mutants disrupting key intermolecular interactions impair vMIA-mediated mitochondrial recruitment of BAX and increase cytochrome c release.\",\n      \"method\": \"NMR structure determination of BAX-vMIA peptide complex, cellular BAX localization assay, cytochrome c release assay, charge-reversal interface rescue mutagenesis\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure with mutagenesis validation and cellular functional confirmation, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"23213219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Bnip3 mediates mitochondrial dysfunction and cell death through Bax and Bak as downstream effectors. BAX/BAK double-deficient MEFs are completely resistant to hypoxia-induced cell death and Bnip3 overexpression, and re-expression of either Bax or Bak restores susceptibility. Bnip3 triggers GFP-Bax translocation to mitochondria during simulated ischemia-reperfusion.\",\n      \"method\": \"Bax/Bak double-knockout MEFs, genetic rescue with Bax or Bak re-expression, GFP-Bax live-cell imaging, mitochondrial membrane potential and cytochrome c assays\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with rescue experiment and multiple functional assays, single lab\",\n      \"pmids\": [\"17447897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Mitochondrial size controlled by Mfn1-mediated fusion is required for productive BAX-membrane interactions. Cells with hyperfragmented mitochondria fail to support BAX-dependent membrane association and permeabilization due to an inability to stabilize BAX α9·membrane interactions. This was demonstrated in biochemical, cellular, in vivo, and size-restricted OMM model systems.\",\n      \"method\": \"Mfn1 genetic manipulation, size-restricted OMM model systems, BAX binding assay, MOMP measurement, in vivo and ex vivo studies\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple complementary systems (biochemical, cellular, in vivo) identifying mechanistic link between mitochondrial size and BAX α9-membrane interaction, single lab\",\n      \"pmids\": [\"25482509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Eltrombopag (FDA-approved drug) directly inhibits BAX by binding the BAX trigger site, preventing BH3-only activators from triggering BAX conformational transformation and simultaneously stabilizing the inactive BAX structure, thereby inhibiting BAX-mediated apoptosis.\",\n      \"method\": \"NMR binding assay, BAX conformational activation assay, cellular apoptosis assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — NMR-confirmed direct binding with functional inhibition assay, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"33602934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Parkin suppresses BAX-mediated apoptosis through an indirect mechanism (not via direct BAX ubiquitination), in contrast to its direct ubiquitination of BAK. The indirect mechanism of BAX suppression by Parkin during mitophagy was established by the absence of BAX ubiquitination alongside functional suppression of BAX activity.\",\n      \"method\": \"Ubiquitination assay, BAX/BAK-deficient genetic analysis, mitophagy induction, apoptosis assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — negative finding (no BAX ubiquitination) combined with functional assay; indirect mechanism proposed but not fully defined, single lab\",\n      \"pmids\": [\"30573668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PGAM5L (long isoform) is required for Bax activation and its translocation to mitochondria during intrinsic apoptosis. A Bax-PGAM5L-Drp1 ternary complex forms during apoptosis; Bax transfection rescues triplex formation in Bax-null cells. Knockdown of PGAM5L inhibits Bax translocation and reduces mitochondrial fission.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, Bax-null cell rescue, GFP-Bax translocation assay, in vivo tumor models\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, genetic rescue, and translocation assays in multiple models, single lab\",\n      \"pmids\": [\"26356820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Cyclin C, released from the nucleus to cytoplasm during oxidative stress, directly co-immunoprecipitates with active BAX and binds recombinant BAX in vitro. Cytoplasmic cyclin C is required for both normal BAX activation and efficient BAX mitochondrial localization. Stable cyclin C-BAX association requires the fission complex.\",\n      \"method\": \"Co-immunoprecipitation of endogenous proteins, in vitro binding with recombinant BAX, cyclin C nuclear release manipulation, BAX activation and localization assay\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vitro binding plus Co-IP and functional localization data, single lab\",\n      \"pmids\": [\"31385392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Bax activates endophilin B1 (Endo B1) oligomerization in a cell-free system: purified Bax induces Endo B1 to assemble into high-molecular-weight oligomers via the Endo B1 C-terminal SH3 domain, without Bax stably associating with the final complex. Together, Bax plus Endo B1 induces massive vesiculation of giant unilamellar vesicles, suggesting Bax regulates mitochondrial membrane remodeling via transient Endo B1 activation.\",\n      \"method\": \"Cell-free reconstitution with purified proteins, size-exclusion chromatography, giant unilamellar vesicle assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro reconstitution establishing transient Bax-Endo B1 interaction and functional membrane vesiculation, single lab\",\n      \"pmids\": [\"19805544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Prostaglandin E2 (PGE2) directly binds BAX and induces a conformational change that triggers apoptosis. Cys126 in the loop between the two transmembrane α-helices is critical for PGE2-induced BAX activation. PGD2 antagonizes PGE2 binding to BAX and inhibits PGE2-induced apoptosis, establishing a PGE2/PGD2 balance as a regulatory mechanism for BAX activation.\",\n      \"method\": \"Direct binding assay (PGE2-BAX), cysteine mutagenesis, apoptosis assays with multiple stimuli\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding with mutagenesis and multiple functional apoptosis assays, single lab\",\n      \"pmids\": [\"20966963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"BAX directly permeabilizes lysosomal membranes (lysosomal membrane permeabilization, LMP) in Parkinson disease models. Recombinant BAX induces LMP in purified mouse brain lysosomes; pharmacological blockade of BAX channel activity prevents LMP. BAX translocates to lysosomal membranes early after MPTP treatment, preceding mitochondrial permeabilization.\",\n      \"method\": \"Recombinant BAX LMP assay in purified lysosomes, BAX channel inhibitor treatment, in vivo and in vitro BAX translocation assay\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro reconstitution with purified lysosomes plus pharmacological validation in vivo and in vitro, single lab\",\n      \"pmids\": [\"24686337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Cholesterol in membrane bilayers inhibits BAX pore-forming activity by reducing the ability of BAX to transition from a membrane-associated to a membrane-integral state. Cholesterol increases BAX binding to membranes but markedly reduces integration into both liposomal and mitochondrial membranes.\",\n      \"method\": \"In vitro BAX membrane binding/integration assay with defined liposomes and isolated human mitochondria, cholesterol titration\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified BAX and defined membranes, mechanistic dissection of binding vs. integration steps, single lab\",\n      \"pmids\": [\"18590739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Unsaturated lipids are enriched in the proximal membrane environment of BAX and BAK during apoptosis. Unsaturated lipids promote BAX pore activity in model membranes, isolated mitochondria, and cellular systems. The fatty acid desaturase FADS2 enhances both apoptosis sensitivity and cGAS/STING pathway activation downstream of mtDNA release.\",\n      \"method\": \"Comparative lipidomics of BAK in lipid nanodiscs, BAX pore activity assay in model membranes and isolated mitochondria, FADS2 manipulation, molecular dynamics simulations\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — lipidomics identification with functional reconstitution in multiple systems and MD simulation support, single lab\",\n      \"pmids\": [\"38830851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TCTP antagonizes apoptosis by inserting into the mitochondrial membrane and inhibiting BAX dimerization. Crystal structure of human TCTP at 2.0 Å revealed structural similarity between TCTP H2-H3 helices and BAX H5-H6 helices. Site-directed mutagenesis of H2-H3 abolished TCTP's anti-apoptotic function.\",\n      \"method\": \"Crystal structure determination (2.0 Å), site-directed mutagenesis of TCTP, mitochondrial insertion assay, BAX dimerization inhibition assay\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with mutagenesis and functional validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"18274553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Cytosolic BAX exists as an ensemble of conformers; distribution within this ensemble determines function. Crystal structure of BAX P168G mutant near the C-terminus and antibody 3C10 binding near the N-terminus both inhibit BAX by limiting exposure of membrane-associating helix α9, supporting an allosteric conformational ensemble model of BAX regulation.\",\n      \"method\": \"Crystal structure determination of BAX P168G and BAX-3C10 antibody complex, functional cytosolic BAX inhibition assays\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures with functional validation, single lab\",\n      \"pmids\": [\"30122452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DRAM1 directly interacts with BAX, inhibits BAX autophagic degradation, recruits BAX to lysosomes, and thereby promotes BAX-mediated lysosomal cathepsin B release, tBID cleavage, and mitochondrial cytochrome c release. BAX at lysosomes thus initiates a lysosome-cathepsin B-tBID pathway leading to apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, BAX protein stability assay, lysosomal fractionation, cathepsin B release assay, cytochrome c release assay\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with multiple functional assays identifying novel BAX localization-function link at lysosomes, single lab\",\n      \"pmids\": [\"25633293\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BAX is a cytosolic, predominantly monomeric (also forming an autoinhibited inactive dimer) pro-apoptotic BCL-2 family protein that, upon apoptotic signaling, undergoes N-terminal conformational activation (triggered by direct-activator BH3-only proteins such as tBID, BIM, PUMA binding a distinct trigger site on BAX), exposes its C-terminal hydrophobic domain for mitochondrial targeting (facilitated by VDAC2 as a membrane platform), oligomerizes at the mitochondrial outer membrane (MOM) through symmetric BH3:groove dimers that further assemble via α6-helix interfaces into rings, arcs, and higher-order structures forming heterogeneous pores (lipidic and/or proteinaceous) that permeabilize the MOM to release cytochrome c and mtDNA; BAX activity is counteracted by pro-survival BCL-2 proteins (notably BCL-xL, which retrotranslocates BAX from mitochondria back to cytosol via VDAC2) and by phosphorylation (Akt at S184, PKCζ at S184) that sequesters BAX in the cytosol; additionally, BAX regulates mitochondrial fusion by activating Mfn2, can permeabilize ER and lysosomal membranes, and its macropores enable herniation of the inner mitochondrial membrane carrying mtDNA to activate innate immune cGAS/STING signaling.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"BAX is a pro-apoptotic BCL-2 family protein that executes mitochondrial outer membrane permeabilization (MOMP), the committed step of intrinsic apoptosis [#0, #7]. In healthy cells BAX is held inactive in the cytosol as a conformational ensemble of monomers and an autoinhibited dimer in which the N-terminal \\u03b11 helix keeps the C-terminal \\u03b19 transmembrane signal-anchor sequestered in the dimerization pocket, preventing mitochondrial insertion [#13, #38, #3, #1]. A death signal relieves this autoinhibition: direct-activator BH3-only proteins (tBID, BIM, PUMA) engage a distinct trigger site, expose \\u03b11, disengage \\u03b19, and drive mitochondrial targeting and homo-oligomerization, with BID acting catalytically and through both BID-dependent and BID-independent routes [#3, #11, #22, #23]. Membrane-inserted BAX undergoes opening of the \\u03b15\\u2013\\u03b16 hairpin and assembles into symmetric dimers that further organize into rings, arcs, and linear oligomers forming pores of variable size [#4, #7, #23]. These pores enlarge into macropores permitting inner-membrane herniation and release of cytochrome c and mtDNA, the latter activating cGAS/STING innate-immune signaling [#6, #36]. VDAC2 serves as the mitochondria-specific platform governing BAX association and is selectively required for BAX (not BAK) apoptotic function [#8, #9]. BAX activity is opposed by pro-survival proteins\\u2014BCL-xL drives retrotranslocation of membrane BAX back to the cytosol, BCL-2 sequesters inserted monomers, and the BCL-2 BH4 domain noncanonically suppresses BAX N-terminal activation [#2, #24, #12]\\u2014and by inhibitory phosphorylation at Ser184 by Akt and PKC\\u03b6 that retains BAX in the cytosol [#19, #20]. Beyond apoptosis, BAX promotes mitochondrial fusion by activating the GTPase Mfn2 in healthy cells and can also permeabilize endoplasmic reticulum and lysosomal membranes [#5, #10, #34]. The membrane environment, including mitochondrial size, cholesterol, and unsaturated lipids, tunes BAX integration and pore activity [#27, #35, #36].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established that BAX is a cytosolic protein that relocates to mitochondria at the onset of apoptosis and that its C-terminal hydrophobic domain is essential for both targeting and killing, defining the spatial logic of BAX activation.\",\n      \"evidence\": \"GFP-fusion live-cell confocal microscopy, FRAP, and domain-deletion death assays in Cos-7/L929 cells\",\n      \"pmids\": [\"9382873\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define what represses targeting in healthy cells\", \"Molecular trigger for translocation unresolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showed that the N-terminal domain represses the C-terminal signal-anchor and that a death signal (partly caspase-dependent) relieves this, explaining how membrane insertion is held in check until apoptosis.\",\n      \"evidence\": \"Domain/chimeric mutagenesis, in vivo and cell-free targeting reconstitution, zVAD-fmk inhibition\",\n      \"pmids\": [\"9763432\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the relieving factor not pinned down\", \"Caspase role only partial\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified tBID as a trigger that relieves N-terminal repression of insertion, while revealing a parallel BID-independent route and uncoupling cytochrome c release from BAX insertion under some conditions.\",\n      \"evidence\": \"In vivo/in vitro mitochondrial targeting reconstitution and Bid-null MEF genetics\",\n      \"pmids\": [\"11139284\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nature of the BID-independent pathway unresolved\", \"Stoichiometry of activation not defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrated BAX/BAK act at the ER as well as mitochondria, defining a parallel ER-stress caspase-12 pathway and broadening BAX's organellar reach.\",\n      \"evidence\": \"Organelle-targeted Bak mutants in bax-/-bak-/- cells, caspase-12 cleavage and ER Ca2+ assays\",\n      \"pmids\": [\"12847083\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BAX selects ER vs mitochondria unclear\", \"Relevance of caspase-12 pathway across species\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified ASC as a p53-dependent adaptor coupling genotoxic stress to BAX mitochondrial translocation, linking upstream stress signaling to BAX activation.\",\n      \"evidence\": \"Co-IP, siRNA knockdown, colocalization, caspase activation assays\",\n      \"pmids\": [\"14730312\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding interface not mapped\", \"Whether ASC activates or merely chaperones BAX unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Revealed a non-death role: BAX promotes mitochondrial fusion in healthy cells by activating Mfn2, showing BAX function is not restricted to apoptosis.\",\n      \"evidence\": \"Bax/Bak knockout cells, live-cell morphology imaging, Mfn2 distribution/mobility studies\",\n      \"pmids\": [\"17035996\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical mechanism of Mfn2 activation undefined\", \"How this role is partitioned from apoptotic function unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed BCL-2 sequesters membrane-inserted BAX monomers via a tBid/Bax-induced conformational change requiring \\u03b15\\u2013\\u03b16 helix mobility, defining a post-insertion inhibitory checkpoint.\",\n      \"evidence\": \"Disulfide-tethered BCL-2 mutant in cells and isolated mitochondria\",\n      \"pmids\": [\"16642033\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Engineered mutant; physiological conformer not directly observed\", \"Single lab\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Established direct phosphorylation of BAX at Ser184 by PKC\\u03b6 as a survival switch that prevents conformational change and dissociates BAX from mitochondria, defining post-translational suppression.\",\n      \"evidence\": \"In vitro kinase assay with purified proteins, phospho-site mutagenesis, Co-IP, mitochondrial dissociation assay\",\n      \"pmids\": [\"17525161\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological contexts of PKC\\u03b6 regulation of BAX limited\", \"Structural basis of S184 effect not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined the stepwise activation mechanism whereby \\u03b11 keeps \\u03b19 in the dimerization pocket and direct activators expose \\u03b11 to release \\u03b19, with activators remaining engaged to drive oligomerization.\",\n      \"evidence\": \"Domain mutagenesis, structural analysis, cellular targeting/oligomerization and BH3 interaction assays\",\n      \"pmids\": [\"19917256\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transient nature of activator engagement not quantified\", \"Membrane requirement not addressed structurally\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Provided a biophysical oligomer model showing BH3:groove dimers nucleate assembly and that BID acts catalytically, establishing the structural unit of the BAX pore.\",\n      \"evidence\": \"EPR with spin-labeled Bax, AFM, cryo-EM, liposome reconstitution\",\n      \"pmids\": [\"20008353\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Higher-order assembly geometry incompletely resolved\", \"Pore lipidic vs proteinaceous nature unsettled\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed BAX transiently activates endophilin B1 oligomerization to vesiculate membranes, implicating BAX in mitochondrial membrane remodeling beyond pore formation.\",\n      \"evidence\": \"Cell-free reconstitution with purified proteins, SEC, GUV vesiculation assay\",\n      \"pmids\": [\"19805544\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro only; cellular relevance not established\", \"BAX does not stably associate, so mechanism transient and hard to validate\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined BCL-xL inhibition as continuous retrotranslocation of membrane BAX back to the cytosol, reframing pro-survival control as a dynamic spatial mechanism rather than static sequestration.\",\n      \"evidence\": \"Disulfide tethering, FLIP, cell-free MOMP assay, Co-IP\",\n      \"pmids\": [\"21458670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular machinery of transport step not fully defined\", \"How activation overrides retrotranslocation unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified HDAC6/Ku70 as a cytosolic restraint that holds BAX inactive in a deacetylated-Ku70 complex, linking acetylation status to BAX availability.\",\n      \"evidence\": \"Co-IP, HDAC6 inhibitor, siRNA knockdown, cell death assay in neuroblastoma\",\n      \"pmids\": [\"21847364\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect binding not separated\", \"Generality beyond neuroblastoma untested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified a distinct BAX trigger site by NMR using a direct small-molecule activator, establishing that BAX can be activated independently of antiapoptotic proteins or BAK.\",\n      \"evidence\": \"Computational screen, NMR interaction analysis, oligomerization and death assays\",\n      \"pmids\": [\"22634637\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In-cell occupancy of the trigger site not measured\", \"Endogenous ligand of trigger site unknown at this stage\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Solved the BAX-vMIA complex by NMR, revealing a viral inhibitory site distinct from canonical surfaces, illustrating an additional regulatable surface on BAX.\",\n      \"evidence\": \"NMR structure of BAX-vMIA peptide, cellular localization and cytochrome c assays, interface rescue mutagenesis\",\n      \"pmids\": [\"23213219\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological host counterpart of this site unknown\", \"Mechanism limited to viral context\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Determined an in-membrane structural model showing active BAX as dimer assemblies with a flexible piercing domain and \\u03b15\\u2013\\u03b16 clamp opening as the central permeabilizing change.\",\n      \"evidence\": \"DEER EPR spectroscopy in liposomes and isolated mitochondria\",\n      \"pmids\": [\"25458844\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic-resolution pore structure still lacking\", \"Higher-order ring/arc connectivity not resolved here\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed BAX can directly permeabilize lysosomal membranes early in Parkinson disease models, extending pore activity to a non-mitochondrial organelle.\",\n      \"evidence\": \"Recombinant BAX LMP assay in purified lysosomes, channel inhibitor, in vivo/in vitro translocation\",\n      \"pmids\": [\"24686337\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Targeting determinants for lysosomes vs mitochondria unknown\", \"Single disease model\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined a noncanonical inhibitory mechanism in which the BCL-2 BH4 domain binds a defined groove on BAX to suppress N-terminal activation, distinct from BH3-groove sequestration.\",\n      \"evidence\": \"HDX-MS, fluorescence polarization binding, BAX activation assay\",\n      \"pmids\": [\"25684204\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular contribution relative to canonical sequestration unquantified\", \"Structural complex not crystallized\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed mitochondrial size controlled by Mfn1-mediated fusion is required for productive BAX \\u03b19\\u00b7membrane interactions, linking organelle morphology to permeabilization competence.\",\n      \"evidence\": \"Mfn1 manipulation, size-restricted OMM models, BAX binding and MOMP assays in vitro/in vivo\",\n      \"pmids\": [\"25482509\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Biophysical basis of size dependence incomplete\", \"Single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified PGAM5L as required for BAX activation/translocation via a Bax-PGAM5L-Drp1 ternary complex, connecting BAX to the fission machinery.\",\n      \"evidence\": \"Co-IP, siRNA, Bax-null rescue, GFP-Bax translocation, tumor models\",\n      \"pmids\": [\"26356820\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs scaffold role of PGAM5L unclear\", \"Interaction interfaces unmapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed DRAM1 binds BAX, blocks its autophagic degradation, and recruits it to lysosomes to initiate a cathepsin B\\u2013tBID amplification loop, defining a lysosome-initiated apoptotic route for BAX.\",\n      \"evidence\": \"Co-IP, stability assay, lysosomal fractionation, cathepsin B and cytochrome c release assays\",\n      \"pmids\": [\"25633293\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding interface unmapped\", \"Generality of lysosomal BAX route uncertain\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Visualized BAX organizing into rings, arcs, and linear assemblies that perforate membranes, establishing that pores can be fully or partially delineated and vary in size.\",\n      \"evidence\": \"Dual-color SMLM super-resolution and AFM on lipid bilayers\",\n      \"pmids\": [\"26783362\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Lipidic vs proteinaceous pore character unresolved\", \"Determinants of arc vs ring choice unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Solved the autoinhibited inactive BAX dimer crystal structure, showing an asymmetric interaction that must dissociate to monomers before activation, defining a cytosolic restraint state.\",\n      \"evidence\": \"Full-length crystal structure, cellular activity and dimerization assays\",\n      \"pmids\": [\"27425408\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Fraction of BAX in dimer vs monomer in cells unclear\", \"Trigger for dissociation undefined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established VDAC2 as the mitochondrial platform ensuring mitochondria-specific BAX retrotranslocation, also tuned by nucleotides and calcium.\",\n      \"evidence\": \"Mitochondrial isolation, retrotranslocation assay, VDAC2 deletion, localization analysis\",\n      \"pmids\": [\"27620692\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of VDAC2-BAX coupling not structurally defined\", \"Where BAX goes without VDAC2 only partly characterized\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified an allosteric sensitizer pocket at the \\u03b13\\u2013\\u03b14/\\u03b15\\u2013\\u03b16 junction that mobilizes the \\u03b11\\u2013\\u03b12 loop and BAX BH3 helix, mapping a druggable activation-promoting surface.\",\n      \"evidence\": \"NMR fragment screen, HDX-MS, biochemical activation assay\",\n      \"pmids\": [\"28692068\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In-cell efficacy of sensitizers limited\", \"Endogenous ligand of pocket unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed BAK/BAX macropores allow inner-membrane herniation and mtDNA release that activates cGAS/STING, connecting MOMP to innate immune signaling.\",\n      \"evidence\": \"Lattice light-sheet and super-resolution imaging of MEFs with BAK/BAX knockout\",\n      \"pmids\": [\"29472455\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular control of macropore enlargement unclear\", \"Timing relative to caspase activation not fully mapped\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established Akt phosphorylation at Ser184 as an apoptosis-to-survival switch that lets BAX bind and sequester activator BH3 proteins while blocking insertion, defining a converging Ser184 regulatory node.\",\n      \"evidence\": \"Phospho-mutagenesis, BH3 binding assay, insertion and apoptosis-resistance assays\",\n      \"pmids\": [\"29987135\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of converted BH3-binding behavior unresolved\", \"Interplay with PKC\\u03b6 at the same site untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated cytosolic BAX is a conformational ensemble whose distribution sets function, with structures showing \\u03b19 exposure as the key tunable element.\",\n      \"evidence\": \"Crystal structures of BAX P168G and BAX-3C10 antibody complex, inhibition assays\",\n      \"pmids\": [\"30122452\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How upstream signals bias the ensemble undefined\", \"Quantitative populations in cells unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established VDAC2 as selectively required for BAX (not BAK) apoptotic function via an unbiased screen, defining a BAX-specific dependency.\",\n      \"evidence\": \"Genome-wide CRISPR screen, VDAC2 deletion, Co-IP, tumor formation assays\",\n      \"pmids\": [\"30478310\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether VDAC2 directly forms the pore platform vs acts as receptor unclear\", \"Structural BAX-VDAC2 interface unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed Parkin suppresses BAX indirectly (no BAX ubiquitination), contrasting with direct BAK ubiquitination and revealing mechanistic divergence between the two effectors during mitophagy.\",\n      \"evidence\": \"Ubiquitination assay, BAX/BAK-deficient analysis, mitophagy and apoptosis assays\",\n      \"pmids\": [\"30573668\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Indirect mechanism not defined\", \"Negative finding; intermediary unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined an allosteric inhibitory pocket near \\u03b15 targeted by small-molecule BAIs that stabilize the hydrophobic core and block translocation/oligomerization, providing a pharmacological off-switch.\",\n      \"evidence\": \"NMR binding, biochemical activation, cellular translocation/oligomerization assays\",\n      \"pmids\": [\"30718816\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In-cell selectivity and potency limited\", \"No endogenous regulator of this pocket identified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified cytoplasmic cyclin C, released during oxidative stress, as a direct BAX-binding factor required for efficient activation and mitochondrial localization, linking stress-driven nuclear release to BAX.\",\n      \"evidence\": \"Co-IP of endogenous proteins, in vitro binding with recombinant BAX, localization assays\",\n      \"pmids\": [\"31385392\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Binding interface unmapped\", \"Requirement for fission complex mechanistically unexplained\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed BAX physically interacts with DRP1 in membranes via its N-terminus and that DRP1 can act as a noncanonical direct activator, integrating the fission GTPase into BAX activation.\",\n      \"evidence\": \"Reciprocal Co-IP, super-resolution imaging, forced dimerization, permeabilization assay\",\n      \"pmids\": [\"35023587\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How DRP1 activation compares to BH3-only activators unclear\", \"In vivo contribution to apoptosis not quantified\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated that unsaturated lipids enrich around BAX/BAK and promote pore activity, and that FADS2 enhances apoptosis and cGAS/STING activation, defining lipid composition as a determinant of permeabilization.\",\n      \"evidence\": \"Comparative lipidomics in nanodiscs, pore assays in model membranes/mitochondria/cells, FADS2 manipulation, MD simulations\",\n      \"pmids\": [\"38830851\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which unsaturation favors integration not atomically defined\", \"Physiological regulation of local lipid pool unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved whether the BAX pore is fundamentally lipidic, proteinaceous, or hybrid, and what unifies the diverse activating inputs (BH3-only proteins, DRP1, cyclin C, PGAM5L, ASC, prostaglandins) into a single quantitative model of pore formation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No atomic-resolution structure of the assembled BAX pore\", \"No integrated kinetic model reconciling the many activators and inhibitors\", \"Determinants of organelle selectivity (mitochondria vs ER vs lysosome) undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [35, 36, 33]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [4, 7, 23]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 16, 32]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 6, 7, 8]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 2, 13, 38]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [10]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [34, 39]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 3, 22, 6]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [5, 27]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 36]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"BCL2L1\", \"VDAC2\", \"BID\", \"DNM1L\", \"MFN2\", \"BCL2\", \"PYCARD\", \"PGAM5\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}